<SEC-DOCUMENT>0001193125-22-311072.txt : 20221222
<SEC-HEADER>0001193125-22-311072.hdr.sgml : 20221222
<ACCEPTANCE-DATETIME>20221222163143
ACCESSION NUMBER:		0001193125-22-311072
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20221222
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Completion of Acquisition or Disposition of Assets
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20221222
DATE AS OF CHANGE:		20221222

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			JOHNSON & JOHNSON
		CENTRAL INDEX KEY:			0000200406
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				221024240
		STATE OF INCORPORATION:			NJ
		FISCAL YEAR END:			0101

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-03215
		FILM NUMBER:		221482335

	BUSINESS ADDRESS:	
		STREET 1:		ONE JOHNSON & JOHNSON PLZ
		CITY:			NEW BRUNSWICK
		STATE:			NJ
		ZIP:			08933
		BUSINESS PHONE:		732-524-2455

	MAIL ADDRESS:	
		STREET 1:		ONE JOHNSON & JOHNSON PLZ
		CITY:			NEW BRUNSWICK
		STATE:			NJ
		ZIP:			08933
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d428734d8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8" ?>
<html xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:us-types="http://fasb.org/us-types/2022" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:jnj="http://www.jnj.com/20221222" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>8-K</title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
   <body><div style="display:none"> <ix:header> <ix:hidden> <ix:nonNumeric id="Hidden_dei_EntityAddressAddressLine1" name="dei:EntityAddressAddressLine1" contextRef="duration_2022-12-22_to_2022-12-22">One Johnson &amp; Johnson Plaza</ix:nonNumeric> <ix:nonNumeric name="dei:AmendmentFlag" contextRef="duration_2022-12-22_to_2022-12-22">false</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_EntityCentralIndexKey" name="dei:EntityCentralIndexKey" contextRef="duration_2022-12-22_to_2022-12-22">0000200406</ix:nonNumeric> </ix:hidden> <ix:references> <link:schemaRef xlink:type="simple" xlink:href="jnj-20221222.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase"></link:schemaRef> </ix:references> <ix:resources> <xbrli:context id="duration_2022-12-22_to_2022-12-22"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-12-22</xbrli:startDate> <xbrli:endDate>2022-12-22</xbrli:endDate> </xbrli:period> </xbrli:context> <xbrli:context id="duration_2022-12-22_to_2022-12-22_us-gaap-StatementClassOfStockAxis_us-gaap-CommonStockMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-12-22</xbrli:startDate> <xbrli:endDate>2022-12-22</xbrli:endDate> </xbrli:period> </xbrli:context> <xbrli:context id="duration_2022-12-22_to_2022-12-22_us-gaap-StatementClassOfStockAxis_jnj-A0.650NotesDue2024Member"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">jnj:A0.650NotesDue2024Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-12-22</xbrli:startDate> <xbrli:endDate>2022-12-22</xbrli:endDate> </xbrli:period> </xbrli:context> <xbrli:context id="duration_2022-12-22_to_2022-12-22_us-gaap-StatementClassOfStockAxis_jnj-A5.50NotesDue2024Member"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">jnj:A5.50NotesDue2024Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-12-22</xbrli:startDate> <xbrli:endDate>2022-12-22</xbrli:endDate> </xbrli:period> </xbrli:context> <xbrli:context id="duration_2022-12-22_to_2022-12-22_us-gaap-StatementClassOfStockAxis_jnj-A1.150NotesDue2028Member"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">jnj:A1.150NotesDue2028Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-12-22</xbrli:startDate> <xbrli:endDate>2022-12-22</xbrli:endDate> </xbrli:period> </xbrli:context> <xbrli:context id="duration_2022-12-22_to_2022-12-22_us-gaap-StatementClassOfStockAxis_jnj-A1.650NotesDue2035Member"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">jnj:A1.650NotesDue2035Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-12-22</xbrli:startDate> <xbrli:endDate>2022-12-22</xbrli:endDate> </xbrli:period> </xbrli:context> </ix:resources> </ix:header> </div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p> <p style="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">UNITED STATES</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">SECURITIES AND EXCHANGE COMMISSION</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">WASHINGTON, DC 20549</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:6pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">FORM <span style="white-space:nowrap"><ix:nonNumeric name="dei:DocumentType" contextRef="duration_2022-12-22_to_2022-12-22">8-K</ix:nonNumeric></span></p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:6pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">CURRENT REPORT</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Pursuant to Section&#160;13 or 15(d)</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">of The Securities Exchange Act of 1934</p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Date of report (Date of earliest event reported):</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="duration_2022-12-22_to_2022-12-22" format="ixt:datemonthdayyearen">December&#160;22, 2022</ix:nonNumeric></p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:6pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman;font-weight:bold;text-align:center"> <ix:nonNumeric name="dei:EntityRegistrantName" contextRef="duration_2022-12-22_to_2022-12-22">Johnson&#160;&amp; Johnson</ix:nonNumeric> </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Exact name of registrant as specified in its charter)</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:32%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="duration_2022-12-22_to_2022-12-22" format="ixt-sec:stateprovnameen">New Jersey</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityFileNumber" contextRef="duration_2022-12-22_to_2022-12-22">1-3215</ix:nonNumeric></span></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="duration_2022-12-22_to_2022-12-22">22-1024240</ix:nonNumeric></span></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(State or Other Jurisdiction</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">of Incorporation)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Commission</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">File Number)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(IRS Employer</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Identification No.)</p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"> <span style=" -sec-ix-hidden:Hidden_dei_EntityAddressAddressLine1">One Johnson&#160;&amp; Johnson Plaza</span> , <ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="duration_2022-12-22_to_2022-12-22">New Brunswick</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="duration_2022-12-22_to_2022-12-22" format="ixt-sec:stateprovnameen">New Jersey</ix:nonNumeric> <ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="duration_2022-12-22_to_2022-12-22">08933</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Address of Principal Executive Offices)</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Zip Code)</p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Registrant&#8217;s telephone number, including area code:</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><span style="white-space:nowrap"><span style="white-space:nowrap"><ix:nonNumeric name="dei:CityAreaCode" contextRef="duration_2022-12-22_to_2022-12-22">732</ix:nonNumeric>-<ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="duration_2022-12-22_to_2022-12-22">524-0400</ix:nonNumeric></span></span></p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form <span style="white-space:nowrap">8-K</span> filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:WrittenCommunications" contextRef="duration_2022-12-22_to_2022-12-22" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:SolicitingMaterial" contextRef="duration_2022-12-22_to_2022-12-22" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Soliciting material pursuant to Rule <span style="white-space:nowrap">14a-12</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14a-12)</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementTenderOffer" contextRef="duration_2022-12-22_to_2022-12-22" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Pre-commencement communications pursuant to Rule <span style="white-space:nowrap">14d-2(b)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14d-2(b))</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" contextRef="duration_2022-12-22_to_2022-12-22" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">13e-4(c)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.13e-4(c))</span></p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule <span style="white-space:nowrap">12b-2</span> of the Securities Exchange Act of 1934 <span style="white-space:nowrap">(&#167;240.12b-2</span> of this chapter).</p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emerging growth company&#160;&#160;<ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="duration_2022-12-22_to_2022-12-22" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act.&#160;&#160;&#9744;</p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities registered pursuant to Section&#160;12(b) of the Act:</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:35%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:31%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Title of each class</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Trading<br />Symbol(s)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Name of each exchange on<br />which registered</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2022-12-22_to_2022-12-22_us-gaap-StatementClassOfStockAxis_us-gaap-CommonStockMember">Common Stock, Par Value $1.00</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2022-12-22_to_2022-12-22_us-gaap-StatementClassOfStockAxis_us-gaap-CommonStockMember">JNJ</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="duration_2022-12-22_to_2022-12-22_us-gaap-StatementClassOfStockAxis_us-gaap-CommonStockMember" format="ixt-sec:exchnameen">New York Stock Exchange</ix:nonNumeric></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2022-12-22_to_2022-12-22_us-gaap-StatementClassOfStockAxis_jnj-A0.650NotesDue2024Member">0.650% Notes Due May 2024</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2022-12-22_to_2022-12-22_us-gaap-StatementClassOfStockAxis_jnj-A0.650NotesDue2024Member">JNJ24C</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="duration_2022-12-22_to_2022-12-22_us-gaap-StatementClassOfStockAxis_jnj-A0.650NotesDue2024Member" format="ixt-sec:exchnameen">New York Stock Exchange</ix:nonNumeric></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2022-12-22_to_2022-12-22_us-gaap-StatementClassOfStockAxis_jnj-A5.50NotesDue2024Member">5.50% Notes Due November 2024</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2022-12-22_to_2022-12-22_us-gaap-StatementClassOfStockAxis_jnj-A5.50NotesDue2024Member">JNJ24BP</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="duration_2022-12-22_to_2022-12-22_us-gaap-StatementClassOfStockAxis_jnj-A5.50NotesDue2024Member" format="ixt-sec:exchnameen">New York Stock Exchange</ix:nonNumeric></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2022-12-22_to_2022-12-22_us-gaap-StatementClassOfStockAxis_jnj-A1.150NotesDue2028Member">1.150% Notes Due November 2028</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2022-12-22_to_2022-12-22_us-gaap-StatementClassOfStockAxis_jnj-A1.150NotesDue2028Member">JNJ28</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="duration_2022-12-22_to_2022-12-22_us-gaap-StatementClassOfStockAxis_jnj-A1.150NotesDue2028Member" format="ixt-sec:exchnameen">New York Stock Exchange</ix:nonNumeric></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2022-12-22_to_2022-12-22_us-gaap-StatementClassOfStockAxis_jnj-A1.650NotesDue2035Member">1.650% Notes Due May 2035</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2022-12-22_to_2022-12-22_us-gaap-StatementClassOfStockAxis_jnj-A1.650NotesDue2035Member">JNJ35</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="duration_2022-12-22_to_2022-12-22_us-gaap-StatementClassOfStockAxis_jnj-A1.650NotesDue2035Member" format="ixt-sec:exchnameen">New York Stock Exchange</ix:nonNumeric></td></tr></table> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p></div></div>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#160;1.01</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Entry into a Material Definitive Agreement. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As previously disclosed, on October&#160;31, 2022, Johnson&#160;&amp; Johnson, a New Jersey corporation (&#8220;<span style="text-decoration:underline">Johnson</span><span style="text-decoration:underline"></span><span style="text-decoration:underline">&#160;&amp; Johnson</span>&#8221;), entered into an Agreement and Plan of Merger (the &#8220;<span style="text-decoration:underline">Merger Agreement</span>&#8221;) with Athos Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Johnson&#160;&amp; Johnson (&#8220;<span style="text-decoration:underline">Purchaser</span>&#8221;), and ABIOMED, Inc., a Delaware corporation (&#8220;<span style="text-decoration:underline">ABIOMED</span>&#8221;). </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the Merger Agreement and in connection with the irrevocable acceptance for payment by Purchaser of all of the outstanding shares of common stock, par value $0.01 per share, of ABIOMED (the &#8220;<span style="text-decoration:underline">Shares</span>&#8221;) validly tendered and not properly withdrawn pursuant to the Offer (as defined below), on December&#160;22, 2022, Johnson&#160;&amp; Johnson and American Stock Transfer&#160;&amp; Trust Company, LLC, a New York limited liability trust company, entered into a Contingent Value Rights Agreement (the &#8220;<span style="text-decoration:underline">CVR Agreement</span>&#8221;) governing the terms of the CVRs (as defined below) issued pursuant to the Offer and the Merger (as defined below). </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each CVR represents the <span style="white-space:nowrap">non-tradeable</span> contractual right to receive contingent cash payments of up to $35.00 per Share in cash, without interest and less any required withholding taxes, in the aggregate (the &#8220;<span style="text-decoration:underline">Milestone Payments</span>&#8221;), payable as specified upon the achievement of the following milestones (each, a &#8220;<span style="text-decoration:underline">Milestone</span>&#8221;): </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(a)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">$17.50 per CVR, if aggregate worldwide Net Sales (as defined in the CVR Agreement) of the Products (as defined in the CVR Agreement) exceeds $3,700,000,000 (the &#8220;<span style="text-decoration:underline">Net Sales Milestone</span>&#8221;) during the period from the first day of Johnson&#160;&amp; Johnson&#8217;s fiscal second quarter of 2027 through the last day of Johnson&#160;&amp; Johnson&#8217;s fiscal first quarter of 2028 (the &#8220;<span style="text-decoration:underline">2028 Measurement Period</span>&#8221;); provided that in the event that the Net Sales Milestone is not achieved during the 2028 Measurement Period, if the Net Sales Milestone is thereafter achieved during any other period of four consecutive fiscal quarters during the period from the first day of Johnson&#160;&amp; Johnson&#8217;s fiscal third quarter of 2027 through the last day of Johnson&#160;&amp; Johnson&#8217;s fiscal first quarter of 2029, the Milestone Payment payable upon the achievement of the Net Sales Milestone will be $8.75 per CVR; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(b)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">$7.50 per CVR, if, on or prior to January&#160;1, 2028, the U.S. Food and Drug Administration approves a premarket approval application or a premarket approval application supplement for the use of any device in the Impella Product Family (as defined in the CVR Agreement) in patients presenting with <span style="white-space:nowrap">ST-Segment</span> Elevation Myocardial Infarction (&#8220;<span style="text-decoration:underline">STEMI</span>&#8221;), or Anterior STEMI, without cardiogenic shock (the &#8220;<span style="text-decoration:underline">FDA Approval Milestone</span>&#8221;); and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(c)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">$10.00 per CVR, upon the earliest to occur of any of the following: </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">(i)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">on or prior to the earlier of (A)&#160;four years after publication of results relating to the secondary clinical endpoint in the STEMI DTU<sup style="font-size:75%; vertical-align:top">&#8482;</sup> study undertaken by ABIOMED and (B)&#160;December&#160;31, 2029, results from the STEMI DTU<sup style="font-size:75%; vertical-align:top">&#8482;</sup> study undertaken by ABIOMED contribute to the publication of a Class&#160;I recommendation in the American College of Cardiology / American Heart </p></td></tr></table>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:13%">&#160;</td>
<td align="left" style="vertical-align:top">
Association Clinical Practice Guideline for Coronary Artery Revascularization (the &#8220;<span style="text-decoration:underline">Clinical Practice Guideline</span>&#8221;) for the use of any device in the Impella Product Family in patients presenting with STEMI, or Anterior STEMI, without cardiogenic shock (the &#8220;<span style="text-decoration:underline">STEMI Recommendation Milestone</span>&#8221;); </td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">(ii)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">on or prior to the earlier of (A)&#160;four years after publication of results relating to the primary clinical endpoints in the PROTECT IV study undertaken by ABIOMED and (B)&#160;December&#160;31, 2029, results from the PROTECT IV study undertaken by ABIOMED contribute to the publication of a Class&#160;I recommendation in the Clinical Practice Guideline for the use of any device in the Impella Product Family in high-risk patients with complex coronary artery disease and reduced left ventricular function (the &#8220;<span style="text-decoration:underline">HRPCI Milestone</span>&#8221;); and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">(iii)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">on or prior to the earlier of (A)&#160;four years after publication of results relating to the primary clinical endpoints in the RECOVER IV study undertaken by ABIOMED and (B)&#160;December&#160;31, 2029, results from the RECOVER IV study undertaken by ABIOMED contribute to the publication of a Class&#160;I recommendation in the Clinical Practice Guideline for the use of any device in the Impella Product Family in patients with STEMI-Cardiogenic Shock, or <span style="white-space:nowrap">STEMI-CS</span> (the &#8220;<span style="text-decoration:underline">Cardiogenic Shock Milestone</span>&#8221;). </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The CVR Agreement requires Johnson&#160;&amp; Johnson to, with respect to each of (a)&#160;the STEMI Recommendation Milestone and the FDA Approval Milestone, (b)&#160;the HRPCI Milestone and (c)&#160;the Cardiogenic Shock Milestone, expend at least $37,682,000, $81,495,200 and $39,800,000, respectively, towards the achievement of such Milestone(s), subject to certain exceptions specified in the CVR Agreement. Other than with respect to these commitments, Johnson&#160;&amp; Johnson (i)&#160;has the right, in its sole and absolute discretion, to direct and control the development, marketing, commercialization and sale of the Products in all respects and (ii)&#160;is not otherwise required (expressly or implicitly) to achieve or undertake any level of efforts, or employ any level of resources, to develop, market, commercialize or sell the Products or achieve the Milestones. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">It is possible that none of the Milestones will be achieved, in which case holders of CVRs will not receive any payments with respect to their CVRs. It is not possible to predict whether any payment will become payable with respect to the CVRs. Whether any Milestone required for payment of any Milestone Payment is met will depend on many factors, some of which are outside the control of Johnson&#160;&amp; Johnson and its subsidiaries. There can be no assurance that any of the Milestones will be achieved or that any payment with respect to the CVRs will be made. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The foregoing description of the CVR Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the CVR Agreement, a copy of which is filed as Exhibit 10.1 to this Current Report on Form <span style="white-space:nowrap">8-K</span> and is incorporated herein by reference. </p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#160;2.01</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Completion of Acquisition or Disposition of Assets. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the Merger Agreement, on November&#160;15, 2022, Purchaser commenced a tender offer to acquire all of the outstanding Shares at a price of (a) $380.00 per Share, net to the seller in cash, without interest and less any required withholding taxes (the &#8220;<span style="text-decoration:underline">Cash Amount</span>&#8221;), plus (b)&#160;one <span style="white-space:nowrap">non-tradeable</span> contractual contingent value right per Share (each, a &#8220;<span style="text-decoration:underline">CVR</span>&#8221;), which CVR represents the right to receive contingent payments of up to $35.00 per Share in cash, without interest and less any required withholding taxes, in the aggregate, upon the achievement of the Milestones (the Cash Amount plus one CVR, collectively, the &#8220;<span style="text-decoration:underline">Offer Price</span>&#8221;), upon the terms and subject to the conditions set forth in the Offer to Purchase, dated November&#160;15, 2022 (as amended or supplemented from time to time, the &#8220;<span style="text-decoration:underline">Offer to Purchase</span>&#8221;) and in the related Letter of Transmittal (together with the Offer to Purchase and other related materials, as amended or supplemented from time to time, the &#8220;<span style="text-decoration:underline">Offer</span>&#8221;). </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On December&#160;22, 2022, Johnson&#160;&amp; Johnson announced that the Offer had expired at 11:59 p.m., New York City time, on December&#160;21, 2022 (the &#8220;<span style="text-decoration:underline">Expiration Time</span>&#8221;) and that as of such time, based on the information provided by the depositary for the Offer, 25,759,195&#160;Shares were validly tendered and not properly withdrawn pursuant to the Offer, representing approximately 57.1% of the then-outstanding Shares, which Shares were sufficient to have met the Minimum Condition (as defined in the Merger Agreement) of the Offer and to enable the Merger (as defined below) to occur in accordance with Section&#160;251(h) of the Delaware General Corporation Law (the &#8220;<span style="text-decoration:underline">DGCL</span>&#8221;) without a vote on the adoption of the Merger Agreement by ABIOMED stockholders. All conditions to the Offer having been satisfied, Purchaser subsequently irrevocably accepted for payment all Shares validly tendered and not properly withdrawn prior to the Expiration Time, and will promptly pay for such Shares pursuant to the Offer. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Following the completion of the Offer, on December&#160;22, 2022, pursuant to the terms of the Merger Agreement and in accordance with Section&#160;251(h) of the DGCL, Purchaser merged with and into ABIOMED (the &#8220;<span style="text-decoration:underline">Merger</span>&#8221;), with ABIOMED continuing as the surviving corporation in the Merger and thereby becoming a wholly owned subsidiary of Johnson&#160;&amp; Johnson. At the closing of the Merger, each Share outstanding immediately prior to the effective time of the Merger (the &#8220;<span style="text-decoration:underline">Effective Time</span>&#8221;) (other than (a)&#160;Shares owned by Johnson&#160;&amp; Johnson, Purchaser or ABIOMED (or held in ABIOMED&#8217;s treasury), or by any direct or indirect wholly owned subsidiary of Johnson&#160;&amp; Johnson or Purchaser, in each case at the commencement of the Offer and immediately prior to the Effective Time, (b)&#160;Shares irrevocably accepted for purchase pursuant to the Offer or (c)&#160;Shares owned by any stockholders who have properly and validly demanded their appraisal rights in compliance with Section&#160;262 of the DGCL) was converted into the right to receive the Offer Price, without interest and less any required withholding taxes. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the terms of the Merger Agreement, at the Effective Time: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">each stock option to purchase Shares (an &#8220;<span style="text-decoration:underline">ABIOMED Option</span>&#8221;) outstanding as of immediately prior to the Effective Time with an exercise price that is less than the Cash Amount (an &#8220;<span style="text-decoration:underline"><span style="white-space:nowrap"><span style="white-space:nowrap">In-the-Money</span></span> Option</span>&#8221;) was canceled in exchange for the Cash Amount (less the applicable exercise price) plus one CVR, in each case, multiplied by the number of Shares underlying such <span style="white-space:nowrap"><span style="white-space:nowrap">In-the-Money</span></span> Option; </p></td></tr></table>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">each ABIOMED Option outstanding as of immediately prior to the Effective Time with an exercise price that is equal to or greater than the Cash Amount (an &#8220;<span style="text-decoration:underline"><span style="white-space:nowrap"><span style="white-space:nowrap"><span style="white-space:nowrap">Out-of-the-Money</span></span></span> Option</span>&#8221;) was canceled in exchange for the right to receive cash payments equal to the total amount of the Milestone Payments actually payable in connection with a CVR (if any), less the amount by which such exercise price exceeds the Cash Amount (if any), multiplied by the number of Shares underlying such <span style="white-space:nowrap"><span style="white-space:nowrap"><span style="white-space:nowrap">Out-of-the-Money</span></span></span> Option; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">each performance stock unit in respect of Shares (an &#8220;<span style="text-decoration:underline">ABIOMED PSU</span>&#8221;) outstanding as of immediately prior to the Effective Time was canceled in exchange for the Cash Amount plus one CVR, in each case, multiplied by the number of Shares underlying such ABIOMED PSU, generally determined based on actual performance for any performance periods that have been completed as of the Effective Time and maximum performance for all other performance periods; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">each restricted stock unit in respect of Shares (an &#8220;<span style="text-decoration:underline">ABIOMED RSU</span>&#8221;) outstanding as of immediately prior to the Effective Time was canceled in exchange for the Cash Amount plus one CVR, in each case, multiplied by the number of Shares underlying such ABIOMED RSU. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The aggregate amount paid by Purchaser in the Offer and the Merger for the Shares was approximately $17.1&#160;billion, excluding related fees and expenses. Johnson&#160;&amp; Johnson and Purchaser funded the acquisition of the Shares in the Offer and the Merger through a combination of Johnson&#160;&amp; Johnson&#8217;s available cash on hand and short-term financing. Johnson&#160;&amp; Johnson estimates that it would need approximately $1.6&#160;billion to pay the maximum aggregate amount that the holders of CVRs and holders of certain options would be entitled to if all of the Milestones are achieved. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The foregoing description of the Merger Agreement and the related transactions does not purport to be complete and is qualified in its entirety by reference to the full text of the Merger Agreement, a copy of which was filed as Exhibit 2.1 to the Current Report on Form <span style="white-space:nowrap">8-K</span> filed by Johnson&#160;&amp; Johnson on November&#160;1, 2022 and is incorporated herein by reference. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#160;7.01</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Regulation FD Disclosure. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On December&#160;22, 2022, Johnson&#160;&amp; Johnson issued a press release announcing, among other things, the consummation of the Merger. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The information contained in this Item 7.01 and in Exhibit 99.1 of this Current Report on Form <span style="white-space:nowrap">8-K</span> shall not be deemed &#8220;filed&#8221; for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended (the &#8220;<span style="text-decoration:underline">Exchange Act</span>&#8221;), or otherwise subject to the liabilities of that section, nor shall it be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing. </p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#160;9.01</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Financial Statements and Exhibits. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d) Exhibits. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td></td>

<td style="vertical-align:bottom;width:4%"></td>
<td style="width:93%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap" align="center"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:inline-block; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Exhibit<br />No.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:inline-block; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Description</p></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;2.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/200406/000119312522274491/d395813dex21.htm">Agreement and Plan of Merger, dated as of October&#160;31, 2022, by and among Johnson&#160;&amp; Johnson, Athos Merger Sub, Inc. and ABIOMED, Inc. (incorporated herein by reference to Exhibit&#160;2.1 of the Current Report on Form <span style="white-space:nowrap">8-K</span> filed by Johnson&#160;&amp; Johnson with the SEC on November&#160;1, 2022)* </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d428734dex101.htm">Contingent Value Rights Agreement, dated as of December&#160;22, 2022, by and between Johnson&#160;&amp; Johnson and American Stock Transfer&#160;&amp; Trust Company, LLC* </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">99.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d428734dex991.htm">Press Release, dated December&#160;22, 2022 </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">104</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Cover Page Interactive Data File (formatted as Inline XBRL).</td></tr>
</table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:2%;vertical-align:top" align="left">*</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Certain exhibits and schedules have been omitted pursuant to Item 601(b)(2) of Regulation <span style="white-space:nowrap">S-K.</span> Johnson&#160;&amp; Johnson hereby undertakes to furnish supplemental copies of any of the omitted exhibits and schedules upon request by the SEC. </p></td></tr></table>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">SIGNATURES </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0">


<tr>

<td style="width:4%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:45%"></td>

<td style="vertical-align:bottom"></td>
<td style="width:3%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:45%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">Johnson&#160;&amp; Johnson</span></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:0pt">&#160;</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:0pt">&#160;</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(Registrant)</p></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Date:</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">December&#160;22, 2022</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">By:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Laura H. McFalls</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:0pt">&#160;</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:0pt">&#160;</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Laura H. McFalls</p> <p style="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Assistant Secretary</p></td></tr>
</table>
</div></div>

</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>d428734dex101.htm
<DESCRIPTION>EX-10.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">EXECUTION VERSION </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONTINGENT
VALUE RIGHTS AGREEMENT </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">THIS CONTINGENT VALUE RIGHTS AGREEMENT, dated as of December&nbsp;22, 2022 (this
&#147;<U>Agreement</U>&#148;), is entered into by and between Johnson&nbsp;&amp; Johnson, a New Jersey corporation (&#147;<U>Parent</U>&#148;), and American Stock Transfer&nbsp;&amp; Trust Company, LLC, a New York limited liability trust company, as
Rights Agent (the &#147;<U>Rights Agent</U>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RECITALS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, Parent, Athos Merger Sub, Inc., a Delaware corporation and a direct or indirect wholly owned Subsidiary of Parent (&#147;<U>Merger
Sub</U>&#148;), and ABIOMED, Inc., a Delaware corporation (the &#147;<U>Company</U>&#148;), have entered into an Agreement and Plan of Merger, dated as of October&nbsp;31, 2022 (as it may be amended or supplemented from time to time pursuant to the
terms thereof, the &#147;<U>Merger Agreement</U>&#148;), pursuant to which, among other matters, (a)&nbsp;Parent has agreed to cause Merger Sub to commence a tender offer (as it may be extended, amended or supplemented from time to time in
accordance with the Merger Agreement, the &#147;<U>Offer</U>&#148;) to acquire all of the outstanding shares of common stock, par value $0.01 per share, of the Company (&#147;<U>Company Shares</U>&#148;) and (b)&nbsp;as soon as practicable following
the irrevocable acceptance for payment by Merger Sub of the Company Shares pursuant to the Offer, Merger Sub will merge with and into the Company (the &#147;<U>Merger</U>&#148;) in accordance with the DGCL, with the Company surviving the Merger as a
wholly owned direct or indirect Subsidiary of Parent, all upon the terms and subject to the conditions set forth in the Merger Agreement; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, pursuant to the Merger Agreement, (a)&nbsp;in each of the Offer and the Merger, Parent has agreed to provide to the holders of
Company Shares (other than holders of Canceled Company Shares and Dissenting Company Shares) and (b)&nbsp;in the Merger, Parent has agreed to provide to holders of Company RSU Awards, Company PSU Awards and <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">In-the-Money</FONT></FONT> Options, in each case, that are outstanding as of immediately prior to the Effective Time (collectively, the &#147;<U>Covered Equity Awards</U>&#148;), in the case of each of clauses (a)&nbsp;and
(b), the right to receive contingent cash payments as hereinafter described; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, pursuant to Section&nbsp;3.7(d)(ii) of the
Merger Agreement, holders of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Out-of-the-Money</FONT></FONT></FONT> Options may be entitled to receive a contingent payment from Parent or the
Surviving Corporation, subject to the terms of the Merger Agreement, upon each Milestone Notice Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NOW, THEREFORE, in consideration of
the foregoing and the consummation of the transactions referred to above, Parent and the Rights Agent agree, for the equal and proportionate benefit of all Holders (as hereinafter defined), as follows: </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1. DEFINITIONS </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.1. <U>Definitions</U>.
Capitalized terms used but not otherwise defined herein shall have the meanings ascribed to them in the Merger Agreement. As used in this Agreement, the following terms shall have the following meanings: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>2028 Measurement Period</U>&#148; means the period from the first day of the second Fiscal Quarter of 2027 through the last day of
the first Fiscal Quarter of 2028. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>2028 <FONT STYLE="white-space:nowrap">Non-Achievement</FONT> Notice</U>&#148; has
the meaning set forth in <U>Section</U><U></U><U>&nbsp;4.5(a)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>2028&#150;29 Measurement Period</U>&#148; means the period
from the first day of the third Fiscal Quarter of 2027 through the last day of the first Fiscal Quarter of 2029. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Acting
Holders</U>&#148; means, at the time of determination, Holders of not less than 35% of the outstanding CVRs as set forth on the CVR Register. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Agreement</U>&#148; has the meaning set forth in the Preamble. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Applicable Milestone Amount</U>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;2.4(a)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Assignee</U>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;7.3</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Budgeted Amounts</U>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;4.6</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Cardiogenic Shock Milestone</U>&#148; has the meaning set forth in the definition of &#147;Clinical Recommendation Milestone.&#148;
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Clinical Practice Guideline</U>&#148; means the American College of Cardiology / American Heart Association Clinical Practice
Guideline for Coronary Artery Revascularization. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Clinical Recommendation Milestone</U>&#148; means the earliest to occur of any
of the following: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) during the applicable Clinical Recommendation Milestone Period, results from the STEMI DTU<SUP
STYLE="font-size:75%; vertical-align:top">&#153;</SUP> study undertaken by the Company contribute to the publication of a Class&nbsp;I recommendation in the Clinical Practice Guideline recommending the use of any device in the Impella Product Family
in patients presenting with <FONT STYLE="white-space:nowrap">ST-Segment</FONT> Elevation Myocardial Infarction (&#147;<U>STEMI</U>&#148;), or Anterior STEMI, without cardiogenic shock (such milestone, the &#147;<U>STEMI Recommendation
Milestone</U>&#148;); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) during the applicable Clinical Recommendation Milestone Period, results from the PROTECT IV study undertaken by
the Company contribute to the publication of a Class&nbsp;I recommendation in the Clinical Practice Guideline recommending the use of any device in the Impella Product Family in high-risk patients with complex coronary artery disease and reduced
left ventricular function (such milestone, the &#147;<U>HRPCI Milestone</U>&#148;); and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) during the applicable Clinical Recommendation
Milestone Period, results from the RECOVER IV study undertaken by the Company contribute to the publication of a Class&nbsp;I recommendation in the Clinical Practice Guideline recommending the use of any device in the Impella Product Family in
patients with STEMI-Cardiogenic Shock, or <FONT STYLE="white-space:nowrap">STEMI-CS</FONT> (such milestone, the &#147;<U>Cardiogenic Shock Milestone</U>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Clinical Recommendation Milestone Period</U>&#148; means, (a)&nbsp;with respect to the STEMI Recommendation Milestone, the period
commencing as of the date of this Agreement and ending on the earlier of (i)&nbsp;four (4) years after publication of results relating to the secondary clinical endpoint in the STEMI DTU<SUP STYLE="font-size:75%; vertical-align:top">&#153;</SUP>
study undertaken by the Company and (ii)&nbsp;December&nbsp;31, 2029, (b)&nbsp;in the case of the HRPCI Milestone, the period commencing as of the date of this Agreement </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and ending on the earlier of (i)&nbsp;four (4) years after publication of results relating to the primary clinical endpoints in the PROTECT IV study undertaken by the Company and
(ii)&nbsp;December&nbsp;31, 2029, and (c)&nbsp;in the case of the Cardiogenic Shock Milestone, the period commencing as of the date of this Agreement and ending on the earlier of (i)&nbsp;four (4)&nbsp;years after publication of results relating to
the primary clinical endpoints in the RECOVER IV study undertaken by the Company and (ii)&nbsp;December&nbsp;31, 2029. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Company</U>&#148; has the meaning set forth in the Recitals. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Company Sale</U>&#148; means the sale, transfer, conveyance, exclusive license or other disposition by Parent or any of its
Subsidiaries (including the Surviving Corporation) to a third party of all or substantially all of the Product portfolio. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Company Shares</U>&#148; has the meaning set forth in the Recitals. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Covered Equity Awards</U>&#148; has the meaning set forth in the Recitals. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Covered Milestone Payments</U>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;2.4(f)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>CVR Register</U>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;2.3(b)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>CVRs</U>&#148; means the contractual rights of Holders to receive contingent cash payments pursuant to the Merger Agreement and this
Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>DTC</U>&#148; means The Depository Trust Company or any successor entity thereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Event of Default</U>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;6.1</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Expiry Notice</U>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;4.5(b)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>FDA Approval Milestone</U>&#148; means the approval by the FDA, during the FDA Approval Milestone Period, of a premarket approval
application or a premarket approval application supplement for the use of any device in the Impella Product Family in patients presenting with STEMI, or Anterior STEMI, without cardiogenic shock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>FDA Approval Milestone Period</U>&#148; means the period commencing as of the date of this Agreement and ending on January&nbsp;1,
2028. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Fiscal Quarter</U>&#148; means a fiscal quarter of any fiscal year of Parent, based on Parent&#146;s universal fiscal
calendar. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>GAAP</U>&#148; means generally accepted accounting principles, as applied in the United States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Holder</U>&#148; means a Person in whose name a CVR is registered in the CVR Register at the applicable time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>HRPCI Milestone</U>&#148; has the meaning set forth in the definition of &#147;Clinical Recommendation Milestone.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Impella Product Family</U>&#148; means Impella CP, Impella RP, Impella 5.5, Impella
ECP, Impella Apto, and any future or improved versions of the foregoing, including any related micro axial heart pumps and percutaneous ventricular assist devices in research or development by the Company as of the date of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Independent Accountant</U>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;4.5(c)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Measurement Period</U>&#148; means any of the 2028 Measurement Period or the 2028&#150;29 Measurement Period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Merger</U>&#148; has the meaning set forth in the Recitals. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Merger Agreement</U>&#148; has the meaning set forth in the Recitals. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Merger Sub</U>&#148; has the meaning set forth in the Recitals. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Milestone Notice</U>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;2.4(a)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Milestone Notice Date</U>&#148; means, (a)&nbsp;with respect the Net Sales Milestone, the date that is forty-five (45)&nbsp;days
following the last day of the (i) 2028 Measurement Period or (ii)&nbsp;the Fiscal Quarter in the 2028&#150;29 Measurement Period, as applicable, in which the Net Sales Milestone is achieved and (b)&nbsp;with respect to the FDA Approval Milestone and
the Clinical Recommendation Milestone, the date that is ten (10)&nbsp;Business Days following the achievement of the applicable Milestone. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Milestone Payment</U>&#148; means (a)&nbsp;with respect to the Net Sales Milestone, (i)&nbsp;if the Net Sales Milestone is achieved
during the 2028 Measurement Period, $17.50 per CVR and (ii)&nbsp;if the Net Sales Milestone is achieved during the 2028&#150;29 Measurement Period, $8.75 per CVR, (b)&nbsp;with respect to the FDA Approval Milestone, $7.50 per CVR and (c)&nbsp;with
respect to the Clinical Recommendation Milestone, $10.00 per CVR. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Milestones</U>&#148; means, collectively, the Net Sales
Milestone, the FDA Approval Milestone and the Clinical Recommendation Milestone. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Net Sales</U>&#148; means, in each case as
determined in accordance with the Parent Accounting Practices (or, if the Selling Entity is not Parent or one of its Affiliates, such Selling Entity&#146;s usual and customary accounting methods to the extent not inconsistent with GAAP), the gross
amounts invoiced on sales of the Products (including amounts invoiced with respect to related service agreements or service charges for such Products) by all Selling Entities to any third party purchaser in an
<FONT STYLE="white-space:nowrap">arm&#146;s-length</FONT> transaction, less Permitted Deductions actually taken, paid, accrued, allocated or allowed with respect to the Products; <U>provided</U> that (a)&nbsp;the transfer of Products between or
among any of the Selling Entities will not be considered a sale, except where such Selling Entity is an <FONT STYLE="white-space:nowrap">end-user</FONT> of, and does not further sell, the Products (in which case Net Sales shall be calculated on the
value charged or invoiced to such purchasing Selling Entity, less Permitted Deductions, in each case as determined in accordance with this paragraph), (b) Net Sales shall not include amounts invoiced on sales of the Products by any distributor of
the Selling Entities, acting in the capacity of a distributor and (c)&nbsp;all Net Sales shall be computed in U.S. Dollars, and where any Net Sales are calculated in a currency other than U.S. Dollars, they shall be converted into U.S. Dollars in
accordance with the Parent Accounting Practices and on the same basis and at such times as Parent&#146;s regular financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If any Product is sold or otherwise commercially disposed of for consideration other than
cash between the buyer of the Product and the applicable Selling Entity (other than with respect to Product supplied expressly for sampling purposes), then the gross amount to be included in the calculation of Net Sales shall be the amount that
would have been received had the transaction been conducted for cash. Such amount that would have been received shall be determined by reference to the average selling price of such Product in the relevant jurisdiction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event that (x)&nbsp;Parent or any of its Subsidiaries (including the Surviving Corporation), directly or indirectly, by a sale or swap
of assets or other rights, merger, reorganization, joint venture, lease, exclusive license or any other transaction or arrangement, sells, transfers, conveys, exclusively licenses or otherwise disposes of, to a Person that is not an Affiliate of
Parent (any such Person, the &#147;<U>Purchaser</U>&#148;), their respective rights in and to any Product that would generate Net Sales after the Closing Date and prior to the end of the <FONT STYLE="white-space:nowrap">2028-29</FONT> Measurement
Period, and (y)&nbsp;such transaction does not constitute a Company Sale, such Purchaser shall be deemed to be a Selling Entity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Net Sales Milestone</U>&#148; means the achievement of aggregate worldwide Net Sales in excess of $3,700,000,000 during the 2028
Measurement Period or, solely in the event that such aggregate worldwide Net Sales is not achieved during the 2028 Measurement Period, during any other period of four consecutive Fiscal Quarters within the 2028&#150;29 Measurement Period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Net Sales Statement</U>&#148; means, for any given Measurement Period, a written statement of Parent, certified by the Chief
Financial Officer of Parent, setting forth with reasonable detail (a)&nbsp;a calculation of Net Sales, (b)&nbsp;a calculation of the Permitted Deductions during such Measurement Period, and (c)&nbsp;to the extent that sales for the Products are
recorded in currencies other than U.S. Dollars during such Measurement Period, the exchange rates used for conversion of such foreign currency into U.S. Dollars. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Offer</U>&#148; has the meaning set forth in the Recitals. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Officer&#146;s Certificate</U>&#148; means a certificate signed by the chief executive officer, president, chief financial officer,
any vice president, the controller, the treasurer or the secretary, in each case of Parent, in his or her capacity as such an officer, and delivered to the Rights Agent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Parent</U>&#148; has the meaning set forth in the Preamble. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Parent Accounting Practices</U>&#148; means, as of any time, GAAP, as applied in a manner consistent with the accounting practices
and methodologies of Parent for SEC reporting purposes in effect at such time (including, as of the date hereof, the application of Accounting Standards Codification 606). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Permitted Deductions</U>&#148; means, in each case as determined in accordance with the Parent Accounting Practices: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) normal and customary trade, cash and quantity discounts, allowances, rebates and credits
actually allowed or paid with respect to sales of the Products (to the extent not already reflected in the amount invoiced and excluding commissions for commercialization); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) retroactive price reductions, allowances or credits actually granted upon rejections or returns of the Products, including for recalls,
returns or damaged goods and for billing errors; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) discounts, chargeback payments, rebates and reimbursements granted to managed care
organizations, group purchasing organizations or other buying groups, health maintenance organizations, Governmental Authorities and any other providers of health insurance coverage, health care organizations or other health care institutions
(including hospitals), health care administrators or patient assistance or other similar programs; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) compulsory payments and cash
rebates related to the sales of the Products actually paid to a Governmental Authority pursuant to governmental regulations by reason of any national or local health insurance program or similar program, including government levied fees as a result
of healthcare reform policies, to the extent such payments and rebates are specifically attributable to sales of such Products or are otherwise allocated to such Products as a percentage of Parent&#146;s and its Affiliates&#146; entire medical
device product sales; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) reasonable and customary outbound freight, shipping, insurance and other transportation expenses, to the extent
actually borne by Parent or its Affiliates without reimbursement from any third party; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) tariffs, duties, excise, sales, value-added,
medical device taxes and other similar Taxes (other than Taxes based on income or profits), customs duties or other charges of a Governmental Authority, in each case imposed on the sale of any Product, including value-added Taxes, but only to the
extent that such value-added Taxes are not reimbursable or refundable; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) amounts written off as uncollectible in accordance with
the Parent Accounting Practices; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>provided</U> that all such discounts, allowances, credits, rebates, reductions, payments, reimbursements, expenses,
Taxes and other deductions shall be allocated among the Products and other products of Parent and its Affiliates that are not included in the Products in accordance with the Parent Accounting Practices. For the avoidance of doubt, if a single item
falls into more than one of the categories set forth in clauses (a)&nbsp;through (g) above, such item may not be deducted more than once. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Permitted Transfer</U>&#148; means a transfer of CVRs (a)&nbsp;upon death of a Holder by will or intestacy; (b)&nbsp;by instrument to
an inter vivos or testamentary trust in which the CVRs are to be passed to beneficiaries upon the death of the trustee; (c)&nbsp;pursuant to a court order; (d)&nbsp;by operation of law (including by consolidation or merger) or without consideration
in connection with the dissolution, liquidation or termination of any corporation, limited liability company, partnership or other entity; (e)&nbsp;in the case of CVRs held in book-entry or other similar nominee form, from a nominee to a beneficial
owner and, if applicable, through an intermediary, as allowable by DTC; or (f)&nbsp;as provided in <U>Section</U><U></U><U>&nbsp;2.6</U>. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Products</U>&#148; means any product that is contemplated for development, in
clinical trials or being manufactured, marketed, sold, commercialized, offered, made available, licensed, distributed or branded by or for the Company or any of its Subsidiaries as of the date of this Agreement, consisting of the products and
proposed products set forth on <U>Exhibit A</U> hereto and any future or improved versions thereof; <U>provided</U>, that, for the avoidance of doubt, any product that Parent or any of its Subsidiaries (including the Surviving Corporation and its
Subsidiaries) may license, sublicense, purchase or otherwise acquire from a third party (whether via a sale or swap of assets or other rights, merger, reorganization, joint venture, lease, exclusive license or any other transaction or arrangement)
after the date of this Agreement shall not be considered a Product. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Purchaser</U>&#148; has the meaning set forth in the
definition of &#147;Net Sales.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Review Request Period</U>&#148; has the meaning set forth in
<U>Section</U><U></U><U>&nbsp;4.5(c)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Rights Agent</U>&#148; means the Rights Agent named in the first paragraph of this
Agreement, until a successor Rights Agent becomes such pursuant to the applicable provisions of this Agreement, and thereafter &#147;Rights Agent&#148; shall mean such successor Rights Agent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Selling Entity</U>&#148; means Parent, any Assignee and each of their respective Affiliates, licensees, sublicensees and agents with
respect to rights to develop or commercialize the Products, and any direct or indirect transferee, successor or assignee (including through any change of control) of the rights to sell the Product of any of the foregoing (but not a distributor of
the Product acting in the capacity of a distributor). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>STEMI</U>&#148; has the meaning set forth in the definition of
&#147;Clinical Recommendation Milestone.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>STEMI Recommendation Milestone</U>&#148; has the meaning set forth in the
definition of &#147;Clinical Recommendation Milestone.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.2. <U>Certain Interpretations</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Unless otherwise indicated, all references herein to Articles, Exhibits or Sections, shall be deemed to refer to Articles, Exhibits or
Sections of or to this Agreement, as applicable, and all references herein to &#147;paragraphs&#148; or &#147;clauses&#148; shall be deemed references to separate paragraphs or clauses of the section or subsection in which the reference occurs. The
words &#147;hereof,&#148; &#147;herein,&#148; &#147;hereby,&#148; &#147;herewith,&#148; &#147;hereunder&#148; and words of similar import shall, unless otherwise stated, be construed to refer to this Agreement as a whole and not to any particular
provision of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Unless otherwise indicated, the words &#147;include,&#148; &#147;includes&#148; and
&#147;including,&#148; when used herein, shall be deemed in each case to be followed by the words &#147;without limitation.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)
Unless otherwise indicated, all references herein to the Subsidiaries of a Person shall be deemed to include all direct and indirect Subsidiaries of such Person unless otherwise indicated or the context otherwise requires. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) If a term is defined as one part of speech (such as a noun), it shall have a
corresponding meaning when used as another part of speech (such as a verb). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) Whenever the context may require, any pronouns used in
this Agreement shall include the corresponding masculine, feminine or neuter forms, and the singular form of nouns and pronouns shall include the plural, and vice versa. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) When used herein, the word &#147;extent&#148; and the phrase &#147;to the extent&#148; shall mean the degree to which a subject or other
thing extends, and such word or phrase shall not simply mean &#147;if.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) The headings set forth in this Agreement are for
convenience of reference purposes only and shall not affect or be deemed to affect in any way the meaning or interpretation of this Agreement or any term or provision hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) References to &#147;$&#148; and &#147;dollars&#148; are to the currency of the United States of America. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) &#147;Writing,&#148; &#147;written&#148; and comparable terms refer to printing, typing and other means of reproducing words (including
electronic media) in a visible form. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(j) Except as otherwise specified, (i)&nbsp;references to any statute shall be deemed to refer to
such statute as amended from time to time and to any rules or regulations promulgated thereunder, (ii)&nbsp;references to any Person include the successors and permitted assigns of that Person, and (iii)&nbsp;references from or through any date mean
from and including or through and including, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(k) Whenever this Agreement refers to a number of days, such number shall
refer to calendar days unless Business Days are specified. Whenever any action must be taken hereunder on or by a day that is not a Business Day, then such action may be validly taken on or by the next day that is a Business Day. Unless otherwise
specified in this Agreement, when calculating the period of time within which, or following which, any action is to be taken pursuant to this Agreement, the date that is the reference day in calculating such period shall be excluded. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(l) The parties hereto agree that they have been represented by counsel during the negotiation and execution of this Agreement and, therefore,
waive the application of any Law, holding or rule of construction providing that ambiguities in an agreement or other document will be construed against the party drafting such agreement or document. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(m) The word &#147;will&#148; shall be construed to have the same meaning as the word &#147;shall.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(n) The word &#147;or&#148; shall be disjunctive but not exclusive. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2. CONTINGENT VALUE RIGHTS </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.1.
<U>CVRs</U>. The CVRs represent the contractual rights of Holders to receive contingent cash payments pursuant to the Merger Agreement and this Agreement. The initial Holders shall be determined pursuant to the terms of the Merger Agreement and this
Agreement, and a list of the initial Holders shall be furnished to the Rights Agent by or on behalf of Parent in accordance with <U>Section</U><U></U><U>&nbsp;4.1</U> hereof. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.2. <U><FONT STYLE="white-space:nowrap">Non-transferable</FONT></U>. The CVRs may not be
sold, assigned, transferred, pledged, encumbered or in any other manner transferred or disposed of, in whole or in part, other than through a Permitted Transfer. Any such sale, assignment, transfer, pledge, encumbrance or disposal that is not a
Permitted Transfer shall be null and void. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.3. <U>No Certificate; Registration; Registration of Transfer; Change of Address</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The CVRs shall not be evidenced by a certificate or other instrument. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) The Rights Agent shall keep a register (the &#147;<U>CVR Register</U>&#148;) for the purpose of registering CVRs in a book-entry position
for each Holder and transfers of CVRs as herein provided. With respect to CVRs that are to be issued to the holders of Company Shares held in book-entry form through DTC, the CVR Register will initially show one (1)&nbsp;position for Cede&nbsp;&amp;
Co. (as nominee of DTC) representing all such CVRs. The Rights Agent will have no responsibility whatsoever directly to the street name holders or DTC participants with respect to transfers of CVRs. With respect to any payments to be made under
<U>Section</U><U></U><U>&nbsp;2.4</U> below, the Rights Agent will accomplish the payment to any former street name holders of the Company Shares by sending a lump sum payment to DTC and the Rights Agent will have no responsibilities whatsoever with
regard to the distribution of payments by DTC to such street name holders. In the case of CVRs to be received by the holders of Covered Equity Awards pursuant to the Merger Agreement, such CVRs will be registered in the name and address of the
holder of such Covered Equity Awards as set forth in the records of the Company at the Effective Time and in a denomination equal to the number of Company Shares subject to such Covered Equity Awards canceled in connection with the Merger. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Subject to the restrictions on transferability set forth in <U>Section</U><U></U><U>&nbsp;2.2</U>, every request made to transfer a CVR
must be in writing and accompanied by a written instrument of transfer and other documentation reasonably requested by the Rights Agent in form reasonably satisfactory to the Rights Agent pursuant to its guidelines, duly executed by the Holder
thereof, the Holder&#146;s attorney duly authorized in writing, the Holder&#146;s personal representative or the Holder&#146;s survivor, as applicable, and setting forth in reasonable detail the circumstances relating to the transfer. Upon receipt
of such written notice, the Rights Agent shall, subject to its reasonable determination that the transfer instrument is in proper form, notify Parent that it has received such written notice. Upon receipt of such notice from the Rights Agent, Parent
shall in good faith reasonably determine whether the transfer otherwise complies with the other terms and conditions of this Agreement (including the provisions of <U>Section</U><U></U><U>&nbsp;2.2</U>), and if Parent so reasonably determines that
it does so comply, Parent shall instruct the Rights Agent in writing to register the transfer of the CVRs in the CVR Register and notify Parent of the same. No service charge shall be made for any registration of transfer of a CVR, but Parent and
the Rights Agent may require payment of a sum sufficient to cover any stamp or other Tax or charge that is imposed in connection with any such registration of transfer. The Rights Agent shall have no duty or obligation to take any action under any
section of this Agreement that requires the payment of applicable Taxes or charges unless and until the Rights Agent is satisfied that all such Taxes or charges have been paid. All duly transferred CVRs registered in the CVR Register shall be the
valid obligations of Parent and shall entitle the transferee to the same benefits and rights under this Agreement as those held immediately prior to the transfer by the transferor. No transfer of a CVR shall be valid unless and until registered in
the CVR Register. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) A Holder may make a written request to the Rights Agent to change such Holder&#146;s
address of record in the CVR Register. The written request must be duly executed by the Holder. Upon receipt of such written request, the Rights Agent is hereby authorized to, and shall promptly, record the change of address in the CVR Register.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.4. <U>Payment Procedures</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) If (i)&nbsp;the Clinical Recommendation Milestone occurs, (ii)&nbsp;the FDA Approval Milestone occurs or (iii)&nbsp;the Net Sales
Milestone is achieved, then, in each case, (A)&nbsp;on or prior to the applicable Milestone Notice Date, Parent shall deliver to the Rights Agent a written notice (each, a &#147;<U>Milestone Notice</U>&#148;) indicating that the applicable Milestone
was achieved and (B)&nbsp;in accordance with <U>Section</U><U></U><U>&nbsp;4.2</U>, Parent shall deliver to the Rights Agent cash, by wire transfer of immediately available funds to an account specified by the Rights Agent, in an amount equal to the
aggregate amount necessary to pay the applicable Milestone Payment to all Holders (each, the &#147;<U>Applicable Milestone Amount</U>&#148;), along with any letter of instruction reasonably required by the Rights Agent; <U>provided</U> that, Parent
may determine, in its sole discretion, that any Covered Milestone Payments shall instead be paid to the applicable Holders through the payroll of the Surviving Corporation or one of its Affiliates and the Applicable Milestone Amount shall be reduced
accordingly for all purposes of this Agreement. Until a Milestone Notice with respect to the applicable Milestone is received by the Rights Agent, the Rights Agent may presume conclusively for all purposes that no event has occurred that would
require the applicable Milestone Payment. For the avoidance of doubt, any Milestone Payment shall only be due once, if at all, and (I)&nbsp;with respect to the achievement of the Net Sales Milestone, regardless of whether Net Sales exceed the
applicable threshold in both Measurement Periods and (II)&nbsp;with respect to the Clinical Recommendation Milestone, regardless of whether any other component of the Clinical Recommendation Milestone may subsequently occur. For the avoidance of
doubt, no publication of a Class&nbsp;I recommendation contemplated by the Clinical Recommendation Milestone or approval of a premarket approval application contemplated by the FDA Approval Milestone occurring after the end of the applicable
Clinical Recommendation Milestone Period or the FDA Approval Milestone Period, as applicable, shall result in any Milestone Payment becoming due and payable. In no event shall Parent be required to pay more than $35.00 per CVR in the aggregate in
the event all Milestones have been achieved. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) In the event that Parent delivers a Milestone Notice, the Rights Agent shall promptly,
and in any event within ten (10)&nbsp;Business Days of receipt of a Milestone Notice, send each Holder at its registered address a copy of such Milestone Notice. Following receipt by the Rights Agent of the Applicable Milestone Amount in accordance
with <U>Section</U><U></U><U>&nbsp;4.2</U>, the Rights Agent shall promptly, and in any event within five (5)&nbsp;Business Days thereof, pay the applicable Milestone Payment to each of the Holders in accordance with the corresponding letter of
instruction delivered by Parent (i)&nbsp;by check mailed to the address of such Holder reflected in the CVR Register as of 5:00 p.m. New York City time on the date of the Milestone Notice or (ii)&nbsp;with respect to any such Holder that is due an
amount in excess of $100,000 in the aggregate who has </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
provided the Rights Agent wiring instructions in writing as of the close of business on the date of the Milestone Notice, by wire transfer of immediately available funds to the account specified
on such instructions. Notwithstanding anything to the contrary in this Agreement, any Covered Milestone Payment that becomes payable pursuant to the Agreement shall be paid no later than March 15th of the calendar year following the calendar year in
which the applicable Milestone is determined to be achieved. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Parent, its Affiliates (including the Surviving Corporation) and the
Rights Agent shall be entitled to, and Parent shall instruct the Rights Agent or its applicable Affiliate to, deduct or withhold from any payments made pursuant to this Agreement such amounts as are required to be deducted or withheld therefrom
under the Code, the U.S. Treasury Regulations thereunder, or any other applicable Tax Law. Prior to making any such Tax withholdings or causing any such Tax withholdings to be made with respect to any Holder (other than payroll withholding and
reporting on the Covered Milestone Payments), the Rights Agent shall (and Parent shall instruct the Rights Agent to), to the extent practicable, provide notice to any Holder of such potential withholding and use commercially reasonable efforts to
solicit from such Holder an IRS Form <FONT STYLE="white-space:nowrap">W-9,</FONT> <FONT STYLE="white-space:nowrap">W-8BEN,</FONT> <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">W-8BEN-E</FONT></FONT> or other applicable Tax form
within a reasonable amount of time in order to provide the opportunity for the Holder to provide such Tax forms to eliminate or reduce such withholding amounts. To the extent any such amounts are so deducted or withheld, such amounts shall be
treated for all purposes under this Agreement and the Merger Agreement as having been paid to the Holder to whom such amounts would otherwise have been paid, and to the extent and within the time period required by applicable Law, Parent shall (or
shall instruct its applicable Affiliate or, other than with respect to any IRS Form <FONT STYLE="white-space:nowrap">W-2,</FONT> the Rights Agent to) deliver to the Holder to whom such amounts would otherwise have been paid an applicable IRS Form
1099, an IRS Form <FONT STYLE="white-space:nowrap">W-2</FONT> or other reasonably acceptable evidence of such withholding. To the extent such amounts are so deducted or withheld by the Rights Agent from any Covered Milestone Payments, the Rights
Agent shall, as soon as reasonably practicable, deliver such amounts to Parent for the purposes of remitting such amounts to the IRS. In no event shall the Rights Agent have any duty, obligation or responsibility for wage or <FONT
STYLE="white-space:nowrap">W-2</FONT> reporting with respect to Milestone Payments (including Covered Milestone Payments) made to the Holders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) Any funds delivered to the Rights Agent for payment to the Holders as Milestone Payments that remain undistributed to the Holders on the
date that is twelve (12)&nbsp;months after the date of the applicable Milestone Notice shall be delivered by the Rights Agent to Parent upon demand, and such Holders shall thereafter look to Parent or the Surviving Corporation, as general creditors
thereof, for any claim to the applicable Milestone Payments that such Holder may be entitled hereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) Neither Parent, the Rights
Agent nor any of their Affiliates shall be liable to any Holder for any amount properly paid to a public official pursuant to any applicable abandoned property, escheat or similar Law. Any amounts remaining unclaimed by such Holders at such time at
which such amounts would otherwise escheat to or become property of any Governmental Authority shall become, to the extent permitted by applicable Laws, the property of the Surviving Corporation or its designee, free and clear of all claims or
interest of any Person previously entitled thereto. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) Except to the extent any portion of any Milestone Payment is required to be treated as
imputed interest pursuant to applicable Law (including Section&nbsp;483 of the Code), the parties hereto intend to treat, for all U.S. federal and applicable state and local income Tax purposes, (i)&nbsp;the CVRs and the Milestone Payments received
with respect to the Company Shares pursuant to the Merger Agreement as additional consideration for the Company Shares and (ii)&nbsp;Milestone Payments paid in respect of each CVR that was received with respect to a Covered Equity Award pursuant to
the Merger Agreement (the &#147;<U>Covered Milestone Payments</U>&#148;), and not the receipt of such CVR, as wages in the year in which the applicable Milestone Payment is made. Parent shall (and shall instruct the Rights Agent to) report for all
Tax purposes in a manner consistent with the foregoing, including by instructing the Rights Agent to deliver to applicable Holders IRS Forms <FONT STYLE="white-space:nowrap">1099-B</FONT> with respect to the receipt of Milestone Payments (other than
Covered Milestone Payments), and none of the parties hereto will take any position to the contrary on any U.S. federal and applicable state and local income Tax Return or for other U.S. federal and applicable state and local income tax purposes
except as required by applicable Law. Notwithstanding the foregoing, Parent shall, and shall instruct the Rights Agent and cause the Surviving Corporation to, report imputed interest with respect to the CVRs and the Milestone Payments pursuant to
Section&nbsp;483 of the Code. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.5. <U>No Voting, Dividends or Interest; No Equity or Ownership Interest</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The CVRs shall not have any voting or dividend rights, and interest shall not accrue on any amounts payable on the CVRs to any Holder.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) The CVRs shall not represent any equity or ownership interest in Parent or in any constituent company to the Merger or any of their
respective Affiliates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.6. <U>Ability to Abandon CVR</U>. A Holder may at any time, at such Holder&#146;s option, abandon all of such
Holder&#146;s remaining rights in a CVR by transferring such CVR to Parent or any of its Affiliates without consideration therefor. Nothing in this Agreement shall prohibit Parent or any of its Affiliates from offering to acquire or acquiring any
CVRs for consideration from the Holders, in private transactions or otherwise, in its sole discretion. Any CVRs acquired by Parent or any of its Affiliates shall be automatically deemed extinguished and no longer outstanding for purposes of the
definition of Acting Holders and Article 5 and Article 6. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3. THE RIGHTS AGENT </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.1. <U>Certain Duties and Responsibilities</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Parent hereby appoints the Rights Agent to act as rights agent for Parent in accordance with the express terms and conditions set forth in
this Agreement (and no implied terms and conditions), and the Rights Agent hereby accepts such appointment. The Rights Agent shall not have any liability for any actions taken, suffered or omitted to be taken in connection with this Agreement,
except to the extent of its gross negligence, bad faith or willful or intentional misconduct. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) The Acting Holders may direct the Rights Agent to act on behalf of the Holders in
enforcing any of their rights hereunder. Notwithstanding the foregoing, the Rights Agent shall be under no obligation to institute any Legal Proceeding, or to take any other action likely to result in the incurrence of material expenses by the
Rights Agent unless the Acting Holders (on behalf of the Holders) shall furnish the Rights Agent with reasonable security and indemnity for any costs and expenses that may be incurred, but this provision shall not affect the power of the Rights
Agent to take such action as the Rights Agent may consider proper, whether with or without any such security or indemnity. All rights of action of any or all Holders under this Agreement may be enforced by the Rights Agent, and any action, suit or
proceeding instituted by the Rights Agent shall be brought in its name as the Rights Agent and any recovery in connection therewith shall be for the proportionate benefit of all the Holders, as their respective rights or interests may appear. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.2. <U>Certain Rights of the Rights Agent</U>. The Rights Agent undertakes to perform such duties and only such duties as are specifically
set forth in this Agreement, and no implied covenants or obligations shall be read into this Agreement against the Rights Agent. In addition: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) in the absence of bad faith, gross negligence or willful misconduct on its part, the Rights Agent may rely and shall be protected and held
harmless by Parent in acting or refraining from acting upon any resolution, certificate, statement, instrument, opinion, report, notice, request, direction, consent, order or other paper or document believed by it in good faith to be genuine and to
have been signed or presented by the proper party or parties; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) whenever the Rights Agent shall deem it desirable that a matter be
proved or established prior to taking, suffering or omitting any action hereunder, the Rights Agent may rely upon an Officer&#146;s Certificate, which certificate shall be full authorization and protection to the Rights Agent, and the Rights Agent
shall, in the absence of gross negligence, bad faith or willful or intentional misconduct on its part, incur no liability and be held harmless by Parent for or in respect of any action taken, suffered or omitted to be taken by it under the
provisions of this Agreement in reliance upon such certificate; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) the Rights Agent may engage and consult with counsel of its selection
and the written advice of such counsel or any opinion of counsel shall be full and complete authorization and protection and shall be held harmless by Parent in respect of any action taken, suffered or omitted by it hereunder in good faith and in
reliance thereon; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) the permissive rights of the Rights Agent to do things enumerated in this Agreement shall not be construed as a
duty; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) the Rights Agent shall not be required to give any note or surety in respect of the execution of such powers or otherwise in
respect of the premises; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) the Rights Agent shall not be liable for or by reason of, and shall be held harmless by Parent with respect
to, any of the statements of fact or recitals contained in this Agreement or be required to verify the same, but all such statements and recitals are and shall be deemed to have been made by Parent only; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) the Rights Agent shall have no liability and shall be held harmless by Parent in respect of the validity of this Agreement or the
execution and delivery hereof (except the due execution and delivery hereof by the Rights Agent and the enforceability of this Agreement against the Rights Agent assuming the due execution and delivery hereof by Parent); nor shall it be responsible
for any breach by Parent of any covenant or condition contained in this Agreement; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) Parent agrees to indemnify the Rights Agent for, and hold the Rights Agent harmless
against, any loss, liability, claim, demands, suits or expense arising out of or in connection with the Rights Agent&#146;s duties under this Agreement, including the reasonable and documented <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> costs and expenses of defending the Rights Agent against any loss, liability, claim, demands, suits or expense, unless such loss has been determined by a final
<FONT STYLE="white-space:nowrap">non-appealable</FONT> judgment of court of competent jurisdiction to be a result of the Rights Agent&#146;s gross negligence, bad faith or willful or intentional misconduct; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) the Rights Agent shall not be liable for any special, punitive, indirect, consequential or incidental loss or damage of any kind
whatsoever (including lost profits) arising out of any act or failure to act hereunder; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(j) Parent agrees (i)&nbsp;to pay the fees and
expenses of the Rights Agent in connection with this Agreement as set forth in Schedule A attached hereto, and (ii)&nbsp;to reimburse the Rights Agent for all Taxes and governmental charges, reasonable and documented
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses and other charges of any kind and nature incurred by the Rights Agent in the execution of this Agreement (other than Taxes imposed on or measured
by the Rights Agent&#146;s net income and franchise or similar Taxes imposed on it (in lieu of net income Taxes)). The Rights Agent shall also be entitled to reimbursement from Parent for all reasonable, documented and necessary <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses paid or incurred by it in connection with the administration by the Rights Agent of its duties hereunder; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(k) notwithstanding anything to the contrary herein, Parent shall not be required to indemnify, hold harmless or reimburse the expenses of the
Rights Agent in connection with any Legal Proceeding commenced by the Rights Agent against Parent; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(l) no provision of this Agreement
shall require the Rights Agent to expend or risk its own funds or otherwise incur any financial liability in the performance of any of its duties hereunder or in the exercise of its rights if there shall be reasonable grounds for believing that
repayment of such funds or adequate indemnification against such risk or liability is not reasonably assured to it. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.3. <U>Resignation
and Removal; Appointment of Successor</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The Rights Agent may resign at any time by giving written notice thereof to Parent
specifying a date when such resignation shall take effect, which notice shall be sent at least thirty (30)&nbsp;days prior to the date so specified but in no event shall such resignation become effective until a successor Rights Agent has been
appointed and accepted such appointment in accordance with <U>Section</U><U></U><U>&nbsp;3.4</U>. Parent has the right to remove the Rights Agent at any time by specifying a date when such removal shall take effect but no such removal shall become
effective until a successor Rights Agent has been appointed and accepted such appointment in accordance with <U>Section</U><U></U><U>&nbsp;3.4</U>. Notice of such removal shall be given by Parent to the Rights Agent, which notice shall be sent at
least thirty (30)&nbsp;days prior to the date so specified. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) If the Rights Agent provides notice of its intent to resign, is removed or becomes
incapable of acting, Parent shall, as soon as is reasonably practicable, appoint a qualified successor Rights Agent who shall be a stock transfer agent of national reputation or the corporate trust department of a commercial bank. Notwithstanding
the foregoing, if Parent shall fail to make such appointment within a period of thirty (30)&nbsp;days after giving notice of such removal or after it has been notified in writing of such resignation or incapacity by the resigning or incapacitated
Rights Agent, then the incumbent Rights Agent may apply to any court of competent jurisdiction for the appointment of a new Rights Agent. The successor Rights Agent so appointed shall, forthwith upon its acceptance of such appointment in accordance
with <U>Section</U><U></U><U>&nbsp;3.4</U>, become the successor Rights Agent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Parent shall give notice of each resignation and each
removal of a Rights Agent and each appointment of a successor Rights Agent through the facilities of DTC in accordance with DTC&#146;s procedures and/or by mailing written notice of such event by first-class mail to the Holders as their names and
addresses appear in the CVR Register. Each notice shall include the name and address of the successor Rights Agent. If Parent fails to send such notice within ten (10)&nbsp;Business Days after acceptance of appointment by a successor Rights Agent,
the successor Rights Agent shall cause the notice to be transmitted at the expense of Parent. Failure to give any notice provided for in this <U>Section</U><U></U><U>&nbsp;3.3</U>, however, shall not affect the legality or validity of the
resignation or removal of the Rights Agent or the appointment of the successor Rights Agent, as the case may be. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.4. <U>Acceptance of
Appointment by Successor</U>. Every successor Rights Agent appointed hereunder shall execute, acknowledge and deliver to Parent and to the retiring Rights Agent an instrument accepting such appointment and a counterpart of this Agreement, and
thereupon such successor Rights Agent, without any further act, deed or conveyance, shall become vested with all the rights, powers, trusts and duties of the retiring Rights Agent. On request of Parent or the successor Rights Agent, the retiring
Rights Agent shall execute and deliver an instrument transferring to the successor Rights Agent all the rights, powers, trusts and duties of the retiring Rights Agent. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">4. <B>COVENANTS</B> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.1. <U>List of
Holders</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Parent shall furnish or cause to be furnished to the Rights Agent, in a form reasonably satisfactory to the Rights
Agent, and received from the Depository Agent in the Offer and the Paying Agent in the Merger (or in the case of Holders who held Covered Equity Awards, the Company), the names and addresses of the Holders promptly upon the Acceptance Time or the
Effective Time, as applicable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Within five (5)&nbsp;Business Days after receipt by the Rights Agent of a written request by any two
(2)&nbsp;or more Holders stating such Holders&#146; desire to communicate with other Holders with respect to their rights under this Agreement, and accompanied by a form of proxy or other communication which the requesting Holders propose to
transmit, the Rights Agent shall elect to either (i)&nbsp;deliver to such requesting Holders all information in the possession or control of the Rights Agent as to the names and addresses of all Holders, or (ii)&nbsp;inform such requesting
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Holders of the approximate number of Holders and the approximate cost of mailing or otherwise transmitting to all Holders the form of proxy or other communication, if any, specified in such
written request. In the event the Rights Agent elects to provide the information specified in <U>Section</U><U></U><U>&nbsp;4.1(b)(ii)</U>, the Rights Agent shall, upon the written request and at the sole expense of the requesting Holders (and the
Rights Agent shall be entitled to invoice such expenses to any single requesting Holder), mail or otherwise transmit to all Holders copies of the applicable form of proxy or other communication within five (5)&nbsp;Business Days after the requesting
Holders (x)&nbsp;have provided to the Rights Agent the material to be mailed or otherwise transmitted and (y)&nbsp;have paid the invoiced expenses of such mailing or transmission to the Rights Agent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.2. <U>Payment of Milestone Payments</U>. If a Milestone has been achieved in accordance with this Agreement, Parent shall, promptly (but in
any event no later than five (5)&nbsp;Business Days) following the delivery of the Milestone Notice, deposit with the Rights Agent, for payment to the Holders in accordance with <U>Section</U><U></U><U>&nbsp;2.4</U>, the Applicable Milestone Amount
in cash. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.3. <U>Books and Records</U>. Parent shall, and shall cause its Subsidiaries to, keep true, complete and accurate records in
sufficient detail to enable the calculation of Net Sales in any applicable Measurement Period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.4. <U>Further Assurances</U>. Parent
agrees that it will perform, execute, acknowledge and deliver or cause to be performed, executed, acknowledged and delivered, all such further and other acts, instruments and assurances as may reasonably be required by the Rights Agent for the
carrying out or performing by the Rights Agent of the provisions of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.5. <U>Notice and Audit Rights</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) If the Net Sales Milestone has not been achieved with respect to the 2028 Measurement Period, Parent shall deliver to the Rights Agent,
within sixty (60)&nbsp;days following the last day of the 2028 Measurement Period, a written notice indicating that the Net Sales Milestone was not achieved during the 2028 Measurement Period (the &#147;<U>2028
<FONT STYLE="white-space:nowrap">Non-Achievement</FONT> Notice</U>&#148;), as well as the Net Sales Statement for such Measurement Period and an Officer&#146;s Certificate making a certification to that effect. The Rights Agent shall promptly, and
in any event within ten (10)&nbsp;Business Days of receipt of the 2028 <FONT STYLE="white-space:nowrap">Non-Achievement</FONT> Notice, send each Holder at its registered address a copy of the 2028
<FONT STYLE="white-space:nowrap">Non-Achievement</FONT> Notice and the Net Sales Statement for such Measurement Period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) If the Net
Sales Milestone has not been achieved with respect to the 2028 Measurement Period and the Net Sales Milestone has also not been achieved with respect to the 2028&#150;29 Measurement Period, Parent shall deliver to the Rights Agent, within sixty
(60)&nbsp;days following the last day of the 2028&#150;29 Measurement Period, a written notice (the &#147;<U>Expiry Notice</U>&#148;) indicating that the Net Sales Milestone was not achieved during the 2028&#150;29 Measurement Period, as well as the
Net Sales Statement for such Measurement Period and an Officer&#146;s Certificate making a certification to that effect. The Rights Agent shall promptly, and in any event within ten (10)&nbsp;Business Days of receipt of the Expiry Notice, send each
Holder at its registered address a copy of the Expiry Notice and the Net Sales Statement for such Measurement Period. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Upon the written request of the Acting Holders provided to Parent within the three
(3)&nbsp;month period following the date on which Parent delivers the 2028 <FONT STYLE="white-space:nowrap">Non-Achievement</FONT> Notice or the Expiry Notice and the applicable Net Sales Statement (the &#147;<U>Review Request Period</U>&#148;),
Parent shall permit one (1)&nbsp;independent certified public accounting firm of nationally recognized standing mutually agreed upon by such Acting Holders and Parent (the &#147;<U>Independent Accountant</U>&#148;) to have access at reasonable times
during normal business hours to the books and records of Parent and its Affiliates pertaining to Net Sales as may be reasonably necessary to evaluate and verify Parent&#146;s determination that the Net Sales Milestone was not achieved during the
applicable Measurement Period; <U>provided</U> that such access shall not unreasonably interfere with the conduct of the business of Parent or any of its Affiliates. Any fees charged by the Independent Accountant shall be borne by the Acting Holders
unless the Independent Accountant determines that Parent&#146;s determination that the Net Sales Milestone was not achieved during the applicable Measurement Period was erroneous, in which case such fees shall be borne by Parent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) No later than thirty (30)&nbsp;days following access to such books and records of Parent and its Affiliates as described in
<U>Section</U><U></U><U>&nbsp;4.5(c)</U>, the Independent Accountant shall deliver a written report to Parent and the Acting Holders of its findings regarding Parent&#146;s determination that the Net Sales Milestone was not achieved during the
applicable Measurement Period. The Independent Accountant shall disclose to the Acting Holders only its conclusion as to Parent&#146;s determination that the Net Sales Milestone was not achieved during the applicable Measurement Period and such
additional information directly related to its conclusion. The Independent Accountant shall provide Parent with a copy of all disclosures made to the Acting Holders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) If the Independent Accountant concludes that Parent&#146;s determination that the Net Sales Milestone was not achieved during the
applicable Measurement Period was erroneous, then, within thirty (30)&nbsp;days of receipt by Parent of such finding, Parent may commence a Legal Proceeding to adjudicate whether the Net Sales Milestone was achieved during the applicable Measurement
Period in accordance with the dispute resolution provisions set forth in <U>Section</U><U></U><U>&nbsp;7.6</U>. If Parent fails to commence such a Legal Proceeding within such thirty (30)&nbsp;day period, the Independent Accountant&#146;s conclusion
shall be final and binding. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) In the event the Acting Holders properly request a review by the Independent Accountant with respect to
the Net Sales Milestone in accordance with <U>Section</U><U></U><U>&nbsp;4.5(c)</U>, the applicable Milestone Payment (or portion thereof) shall not become due and payable (for purposes of <U>Section</U><U></U><U>&nbsp;6.1(a)</U> or otherwise
hereunder), if at all, unless and until (i)&nbsp;the Independent Accountant&#146;s conclusion becomes final and binding in accordance with this <U>Section</U><U></U><U>&nbsp;4.5</U> or (ii)&nbsp;a court of competent jurisdiction issues a final, <FONT
STYLE="white-space:nowrap">non-appealable</FONT> judgment that such amount is properly payable hereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) If, upon the expiration of
the Review Request Period with respect to any Measurement Period, the Acting Holders have not requested a review in accordance with this <U>Section</U><U></U><U>&nbsp;4.5</U>, Parent&#146;s determination that the Net Sales Milestone was not achieved
during such Measurement Period shall be final and binding, and there shall be no further review or remedy allowed relating to the Net Sales Milestone with respect to such Measurement Period. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) Each person seeking to receive information from Parent (including the Independent
Accountant) in connection with a review pursuant to this <U>Section</U><U></U><U>&nbsp;4.5</U> shall enter into a reasonable confidentiality agreement with Parent or any of its Affiliates obligating such person to retain all such information
disclosed to such person pursuant to this <U>Section</U><U></U><U>&nbsp;4.5</U> (including any information provided to any such person by the Independent Accountant) in confidence pursuant to such confidentiality agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) Parent shall not, and shall cause its Affiliates not to, enter into any license or similar agreement with any Selling Entity (other than
Parent or its Affiliates) with respect to rights to develop or commercialize the Products, or any purchase, sale, merger, exclusive license or similar agreement with any Purchaser, in each case, unless such agreement contains provisions that
(i)&nbsp;require such Purchaser to provide records of Net Sales to Parent to allow Parent to comply with the provisions of this Agreement and (ii)&nbsp;would allow any Independent Accountant appointed pursuant to this
<U>Section</U><U></U><U>&nbsp;4.5</U> such access to the records of the other party to such agreement as may be reasonably necessary to perform its duties pursuant to this <U>Section</U><U></U><U>&nbsp;4.5</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(j) The audit rights set forth in this <U>Section</U><U></U><U>&nbsp;4.5</U> may not be exercised by the Acting Holders more than once with
respect to the <FONT STYLE="white-space:nowrap">non-achievement</FONT> of the Net Sales Milestone in each of the 2028 Measurement Period and the 2028&#150;29 Measurement Period. For the avoidance of doubt, the audit rights set forth in this
<U>Section</U><U></U><U>&nbsp;4.5</U> shall not apply to the FDA Approval Milestone or the Clinical Recommendation Milestone. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.6.
<U>Efforts</U>. With respect to each of (a)&nbsp;the STEMI Recommendation Milestone and the FDA Approval Milestone, (b)&nbsp;the HRPCI Milestone and (c)&nbsp;the Cardiogenic Shock Milestone, Parent will expend at least the respective amounts set
forth on <U>Annex A</U> towards the achievement of such Milestone(s) (including completion of the applicable clinical trial related to such Milestone(s)) (the &#147;<U>Budgeted Amounts</U>&#148;); <U>provided</U> that Parent shall not be required to
expend the applicable Budgeted Amount upon any of the following events occurring with respect to the applicable Milestone(s): (i) Parent determines to suspend or terminate the clinical protocol or study contemplated by such Milestone(s) because an
unanticipated device adverse effect presents an unreasonable risk to the subjects of such clinical protocol or study; (ii)&nbsp;the Data and Safety Monitoring Board recommends that the clinical protocol or study contemplated by such Milestone(s) be
suspended or terminated due to safety concerns or futility; (iii)&nbsp;the FDA determines to suspend the clinical protocol or study contemplated by such Milestone(s); or (iv)&nbsp;the clinical protocol or study contemplated by such Milestone(s) is
otherwise prohibited by applicable Law. Subject to the foregoing sentence in this <U>Section</U><U></U><U>&nbsp;4.6</U>, (A) Parent and its Affiliates shall have the right, in their sole and absolute discretion, to direct and control the
development, marketing, commercialization and sale of the Products in all respects and (B)&nbsp;Parent and its Affiliates shall not otherwise be required (expressly or implicitly) to achieve or undertake any level of efforts, or employ any level of
resources, to develop, market, commercialize or sell the Products or achieve the Milestones. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">5. <B>AMENDMENTS</B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.1. <U>Amendments without Consent of Holders</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Without the consent of any Holders or the Rights Agent, Parent, at any time and from time to time, may enter into one or more amendments
hereto, for any of the following purposes: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) to evidence the succession of another Person as a successor Rights Agent and the
assumption by any such successor of the covenants and obligations of the Rights Agent herein; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) to add to the covenants of Parent
such further covenants, restrictions, conditions or provisions as Parent shall consider to be for the protection of the Holders; <U>provided</U> that, in each case, such provisions do not adversely affect the interests of the Holders; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) to cure any ambiguity, to correct or supplement any provision herein that may be defective or inconsistent with any other provision
herein, or to make any other provisions with respect to matters or questions arising under this Agreement; <U>provided</U> that, in each case, such provisions do not adversely affect the interests of the Holders; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iv) as may be necessary or appropriate to ensure that the CVRs are not subject to registration under the Securities Act, the Exchange Act or
any applicable state securities or &#147;blue sky&#148; laws; <U>provided</U> that, in each case, such provisions do not adversely affect the interests of the Holders; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(v) to evidence the assignment of this Agreement by Parent as provided in <U>Section</U><U></U><U>&nbsp;7.3</U>; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(vi) any other amendments hereto for the purpose of adding, eliminating or changing any provisions of this Agreement, unless such addition,
elimination or change is adverse to the interests of the Holders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Without the consent of any Holders, Parent and the Rights Agent, at
any time and from time to time, may enter into one or more amendments thereto to reduce the number of CVRs, in the event any Holder agrees to renounce such Holder&#146;s rights under this Agreement in accordance with
<U>Section</U><U></U><U>&nbsp;7.4</U> or to transfer CVRs to Parent pursuant to <U>Section</U><U></U><U>&nbsp;2.6</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Promptly after
the execution by Parent and the Rights Agent of any amendment pursuant to the provisions of this <U>Section</U><U></U><U>&nbsp;5.1</U>, Parent shall mail (or cause the Rights Agent to mail) a notice thereof through the facilities of DTC in
accordance with DTC&#146;s procedures and/or by first class mail to the Holders at their addresses as they appear on the CVR Register, setting forth such amendment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.2. <U>Amendments with Consent of Holders</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Subject to <U>Section</U><U></U><U>&nbsp;5.1</U> (which amendments pursuant to <U>Section</U><U></U><U>&nbsp;5.1</U> may be made without
the consent of any Holder or the Rights Agent), with the consent of the Holders of not fewer than a majority of the outstanding CVRs as set forth in the CVR Register, whether evidenced in writing or taken at a meeting of the Holders, Parent and the
Rights Agent may enter into one or more amendments hereto for the purpose of adding, eliminating or changing any provisions of this Agreement, even if such addition, elimination or change is materially adverse to the interest of the Holders. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Promptly after the execution by Parent and the Rights Agent of any amendment pursuant to
the provisions of this <U>Section</U><U></U><U>&nbsp;5.2</U>, Parent shall transmit (or cause the Rights Agent to transmit) a notice thereof through the facilities of DTC in accordance with DTC&#146;s procedures and/or by first class mail to the
Holders at their addresses as they appear on the CVR Register, setting forth such amendment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.3. <U>Execution of Amendments</U>. Prior
to executing any amendment permitted by this <U>Section</U><U></U><U>&nbsp;5</U>, the Rights Agent shall be entitled to receive, and shall be fully protected in relying upon, an opinion of counsel selected by Parent stating that the execution of
such amendment is authorized or permitted by this Agreement. The Rights Agent may, but is not obligated to, enter into any such amendment that affects the Rights Agent&#146;s own obligations, rights, powers, immunities or duties under this Agreement
or otherwise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.4. <U>Effect of Amendments</U>. Upon the execution of any amendment under this <U>Section</U><U></U><U>&nbsp;5</U>, this
Agreement shall be modified in accordance therewith, such amendment shall form a part of this Agreement for all purposes and every Holder shall be bound thereby. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">6. <B>REMEDIES OF THE HOLDERS</B> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.1. <U>Event
of Default</U>. &#147;<U>Event of Default</U>&#148; with respect to the CVRs, means each one of the following events which shall have occurred and be continuing (whatever the reason for such Event of Default and whether it shall be voluntary or
involuntary or be effected by operation of Law or pursuant to any judgment, decree or order of any court or any order, rule or regulation of any Governmental Authority): </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) default in the payment by Parent pursuant to the terms of this Agreement of all or any part of any Milestone Payment after a period of
five (5)&nbsp;Business Days after such Milestone Payment shall become due and payable; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) material default in the performance, or
breach in any material respect, of any covenant or warranty of Parent hereunder (other than a payment default described in clause (a)), and continuance of such default or breach for a period of thirty (30)&nbsp;days after a written notice specifying
such default or breach and requiring it to be remedied is given, which written notice states that it is a &#147;Notice of Default&#148; hereunder and is sent by registered or certified mail to Parent and the Rights Agent by the Acting Holders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an Event of Default described above occurs and is continuing (and has not been cured or waived), then, and in each and every such case, the Acting Holders,
following notice in writing to Parent and the Rights Agent, may, in their discretion and at their own expense, commence a Legal Proceeding to protect the rights of the Holders, including to obtain payment for any amounts then due and payable.
Notwithstanding anything herein to the contrary, damages directly resulting from and in the event of an Event of Default shall be the sole and exclusive remedy of any and all Holders for any claims or causes of action (whether in contract, tort or
statute) that may be based upon, arise out of or relate to this Agreement or the CVRs, or the negotiation, execution or performance hereof or thereof or the transactions contemplated hereby. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.2. <U>Suits by Holders</U>. Except for the express rights of the Rights Agent set forth herein, including as set forth in
<U>Section</U><U></U><U>&nbsp;3.1(b)</U>, the Acting Holders will have the sole right, on behalf of all Holders, by virtue of or under any provision of this Agreement, to institute a Legal Proceeding with respect to this Agreement, and no individual
Holder or other group of Holders, nor the Rights </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Agent on behalf thereof, will be entitled to exercise such rights. Notwithstanding the foregoing, in the event of an insolvency proceeding of Parent, individual Holders shall be entitled to
assert claims in such insolvency proceeding and take related actions in pursuit of such claims with respect to any payment that may be claimed by or on behalf of Parent or by any creditor of Parent. Notwithstanding any other provision in this
Agreement, the right of any Holder of any CVR to receive payment of the amounts that a Milestone Notice indicates are payable in respect of such CVR on or after the applicable due date shall not be impaired or affected without the consent of such
Holder. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">7. <B>OTHER PROVISIONS OF GENERAL APPLICATION</B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.1. <U>Notices to the Rights Agent and Parent</U>. All notices and other communications required or permitted to be delivered to Parent or the
Rights Agent hereunder shall be in writing and delivered by email, and shall be deemed to have been duly delivered and received hereunder on the date of dispatch by the sender thereof (to the extent that no &#147;bounce back&#148; or similar message
indicating <FONT STYLE="white-space:nowrap">non-delivery</FONT> is received with respect thereto), in each case, to the intended recipient as set forth below (or to such other recipient as designated in a written notice to the other party hereto in
accordance with this <U>Section</U><U></U><U>&nbsp;7.1</U>): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If to the Rights Agent, to: </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">American Stock Transfer&nbsp;&amp; Trust Company, LLC </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">6201 15<SUP STYLE="font-size:75%; vertical-align:top">th</SUP> Avenue, 2<SUP STYLE="font-size:75%; vertical-align:top">nd</SUP> Floor </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Brooklyn, NY 11219 </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">Attention:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Relationship Management </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">Email:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Reorg_RM@astfinancial.com</U> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">with a copy (which shall not constitute notice) to: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">American Stock Transfer&nbsp;&amp; Trust Company, LLC </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">48 Wall Street, 22<SUP STYLE="font-size:75%; vertical-align:top">nd</SUP> Floor </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">New York, NY 10005 </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">Attention:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Legal Department </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">Email:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">legalteamUS@equiniti.com </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If to Parent, to: </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Johnson&nbsp;&amp; Johnson </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">One
Johnson&nbsp;&amp; Johnson Plaza </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">New Brunswick, NJ 08933 </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">Attention:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Office of General Counsel, Medical Devices </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">Email:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">CVRNOTICE@its.jnj.com </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">with a copy (which shall not constitute notice) to: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Cravath, Swaine&nbsp;&amp; Moore LLP </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Worldwide Plaza </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">
825 Eighth Avenue </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">New York, NY 10019 </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">Attention:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Robert I. Townsend, III </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">George F. Schoen </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Sanjay Murti </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">Email:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">rtownsend@cravath.com </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">gschoen@cravath.com </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">smurti@cravath.com </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.2. <U>Notice to Holders</U>. Where this Agreement provides for notice to Holders, such notice shall be sufficiently given (unless otherwise
herein expressly provided) if in writing and transmitted through the facilities of DTC in accordance with DTC&#146;s procedures or mailed, first-class postage prepaid, to each Holder affected by such event, at the Holder&#146;s address as it appears
in the CVR Register, not later than the latest date, and not earlier than the earliest date, if any, prescribed for the giving of such notice. In any case where notice to Holders is given by mail, neither the failure to mail such notice, nor any
defect in any notice so mailed, to any particular Holder shall affect the sufficiency of such notice with respect to other Holders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.3.
<U>Successors and Assigns</U>. Parent may assign, in its sole discretion and without the consent of any other Person, any or all of its rights, interests and obligations hereunder to (a)&nbsp;one or more direct or indirect wholly owned Subsidiaries
of Parent or (b)&nbsp;any purchaser of the Company and/or the Products in a Company Sale that is a company in the medical devices industry (each permitted assignee under clauses (a)&nbsp;or (b), an &#147;<U>Assignee</U>&#148;); <U>provided</U> that
the Assignee agrees to assume and be bound by all of the terms and conditions of this Agreement. Any such Assignee may thereafter assign, in its sole discretion and without the consent of any other party, any or all of its rights, interests and
obligations hereunder to one or more additional Assignees which agree to assume and be bound by all of the terms and conditions of this Agreement; <U>provided</U>, <U>however</U>, that in connection with any assignment to an Assignee, Parent (or the
other assignor) shall agree to remain liable for the performance by each Assignee (and such other assignor, if applicable) of all covenants, agreements and obligations of Parent hereunder, with such Assignee substituted for Parent under this
Agreement. This Agreement will be binding upon, inure to the benefit of and be enforceable by Parent&#146;s successors and each Assignee. Subject to compliance with the requirements set forth in this <U>Section</U><U></U><U>&nbsp;7.3</U> relating to
assignments, this Agreement shall not restrict Parent&#146;s, any Assignee&#146;s or any of their respective successors&#146; ability to merge or consolidate with, or sell, issue, license or dispose of its stock or other equity interests or assets
to, any other Person, or <FONT STYLE="white-space:nowrap">spin-off</FONT> or <FONT STYLE="white-space:nowrap">split-off.</FONT> Each of Parent&#146;s successors and each Assignee shall, by a supplemental contingent consideration payment agreement or
other acknowledgement executed and delivered to the Rights Agent, expressly assume payment of amounts on all of the CVRs and the performance of every obligation, agreement and covenant of this Agreement on the part of Parent to be performed or
observed. Unless a successor or assignee meets the requirements set forth in <U>Section</U><U></U><U>&nbsp;3.3(b)</U>, the Rights Agent may not assign this Agreement without Parent&#146;s written consent. Any attempted assignment of this Agreement
or any such rights in violation of this <U>Section</U><U></U><U>&nbsp;7.3</U> shall be void and of no effect. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.4. <U>No Third Party Beneficiaries</U>. Nothing in this Agreement, express or implied,
shall give to any Person (other than the Rights Agent and its permitted successors and assigns, Parent, Parent&#146;s successors and Assignees, and the Holders and the Holders&#146; successors and assigns pursuant to Permitted Transfers, each of
whom is intended to be, and is, a third party beneficiary hereunder) any benefit or any legal or equitable right, remedy or claim under this Agreement or under any covenant or provision herein contained, all such covenants and provisions being for
the sole benefit of the Rights Agent and its permitted successors and assigns, Parent, Parent&#146;s successors and Assignees, and the Holders and the Holders&#146; successors and assigns pursuant to Permitted Transfers. The rights hereunder of the
Holders and their successors and assigns pursuant to Permitted Transfers are limited to those expressly provided in this Agreement, and any exercise of such rights by the Holders or their successors and assigns pursuant to Permitted Transfers shall
be subject, in all cases, to the other terms and provisions of this Agreement, including <U>Sections 7.6</U> and <U>7.7</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.5.
<U>Governing Law</U>. This Agreement, including any claims or causes of action (whether in contract, tort or statute) that may be based upon, arise out of or relate to this Agreement or the CVRs, or the negotiation, execution or performance hereof
or thereof or the transactions contemplated hereby, shall be governed by and construed and enforced in accordance with the Laws of the State of Delaware, without giving effect to any choice or conflict of Law provision or rule (whether of the State
of Delaware or any other jurisdiction) that would cause the application of the Laws of any jurisdiction other than the State of Delaware. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.6. <U>Consent to Jurisdiction</U>. Each of the parties hereto (a)&nbsp;irrevocably consents to the service of the summons and complaint and
any other process in any action or proceeding relating to this Agreement, for and on behalf of itself or any of its properties or assets, in accordance with <U>Section</U><U></U><U>&nbsp;7.1</U> or in such other manner as may be permitted by
applicable Law, and nothing in this <U>Section</U><U></U><U>&nbsp;7.6</U> shall affect the right of any party to serve legal process in any other manner permitted by applicable Law; (b)&nbsp;irrevocably and unconditionally consents and submits
itself and its properties and assets in any action or proceeding to the exclusive jurisdiction of the Court of Chancery of the State of Delaware (or, only if the Court of Chancery of the State of Delaware declines to accept or does not have
jurisdiction over a particular matter, any federal or other state court sitting in New Castle County within the State of Delaware) in the event any dispute or controversy arises out of this Agreement or the transactions contemplated hereby, or for
recognition and enforcement of any judgment in respect thereof; (c)&nbsp;agrees that it will not attempt to deny or defeat such personal jurisdiction by motion or other request for leave from any such court; (d)&nbsp;agrees that any actions or
proceedings arising in connection with this Agreement or the transactions contemplated hereby shall be brought, tried and determined only in the Court of Chancery of the State of Delaware (or, only if the Court of Chancery of the State of Delaware
declines to accept or does not have jurisdiction over a particular matter, any federal or other state court sitting in New Castle County within the State of Delaware); (e) waives any objection that it may now or hereafter have to the venue of any
such action or proceeding in any such court or that such action or proceeding was brought in an inconvenient court and agrees not to plead or claim the same; and (f)&nbsp;agrees that it will not bring any action relating to this Agreement or the
transactions contemplated hereby in any court other than the aforesaid courts. Each of the parties hereto agrees that a final judgment in any action or proceeding in such courts as provided above shall be conclusive and may be enforced in other
jurisdictions by suit on the judgment or in any other manner provided by applicable Law. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.7. <U>WAIVER OF JURY TRIAL</U>. EACH OF THE PARTIES HERETO HEREBY IRREVOCABLY WAIVES ALL
RIGHT TO TRIAL BY JURY IN ANY ACTION, PROCEEDING OR COUNTERCLAIM (WHETHER BASED ON CONTRACT, TORT OR OTHERWISE) ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE ACTIONS OF THE PARTIES IN THE NEGOTIATION, ADMINISTRATION, PERFORMANCE AND
ENFORCEMENT HEREOF. EACH PARTY CERTIFIES AND ACKNOWLEDGES THAT (A)&nbsp;NO REPRESENTATIVE, AGENT OR ATTORNEY OF ANY OTHER PARTY HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PARTY WOULD NOT, IN THE EVENT OF LITIGATION, SEEK TO ENFORCE THE
FOREGOING WAIVER, (B)&nbsp;EACH PARTY UNDERSTANDS AND HAS CONSIDERED THE IMPLICATION OF THIS WAIVER, (C)&nbsp;EACH PARTY MAKES THIS WAIVER VOLUNTARILY, AND (D)&nbsp;EACH PARTY HAS BEEN INDUCED TO ENTER INTO THIS AGREEMENT BY, AMONG OTHER THINGS, THE
MUTUAL WAIVERS AND CERTIFICATIONS IN THIS SECTION. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.8. <U>Severability</U>. In the event that any term or other provision of this
Agreement, or the application thereof, is invalid, illegal or incapable of being enforced by any rule of Law, or public policy, all other conditions and provisions of this Agreement shall nevertheless remain in full force and effect. Upon such
determination that any term or other provision is invalid, illegal or incapable of being enforced, the parties hereto shall negotiate in good faith to modify this Agreement so as to effect the original intent of the parties as closely as possible in
a mutually acceptable manner in order for the economic, business and other purposes hereof to be effected as originally contemplated to the fullest extent possible. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.9. <U>Termination</U>. This Agreement shall be terminated and of no force or effect, the parties hereto shall have no liability hereunder
(other than with respect to monies due and owing by Parent to the Rights Agent), and no payments shall be required to be made, upon the earliest to occur of (a)&nbsp;the conclusion of all of the Clinical Recommendation Milestone Periods, the FDA
Approval Milestone Period and the Measurement Periods and the mailing by the Rights Agent to the address of each Holder as reflected in the CVR Register (or payment by wire transfer, as applicable) of any Milestone Payments required to be paid under
the terms of this Agreement and (b)&nbsp;the termination of the Merger Agreement in accordance with its terms. Notwithstanding the foregoing, no such termination shall affect any rights or obligations accrued prior to the effective date of such
termination or <U>Sections 2.4(e)</U>, <U>3.2</U>, <U>7.4</U>, <U>7.5</U>, <U>7.6</U>, <U>7.7</U>, <U>7.8</U>, <U>7.10</U>, <U>7.11</U>, <U>7.13</U>, <U>7.14</U> or this <U>Section</U><U></U><U>&nbsp;7.9</U>, which shall survive the termination of
this Agreement, or the resignation, replacement or removal of the Rights Agent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.10. <U>Entire Agreement</U>. As it relates to the
Rights Agent, this Agreement constitutes the entire agreement among the parties with respect to the subject matter hereof and supersedes all prior agreements and understandings, both written and oral, among the parties with respect to the subject
matter hereof. As between Parent and the Company, this Agreement, the Merger Agreement (including any schedules, annexes and exhibits thereto) and the documents and instruments and other agreements among the parties to the Merger Agreement as
contemplated by or referred to in the Merger Agreement, including the Company Disclosure Letter and the Annexes thereto, and the Confidentiality Agreement, constitute the entire agreement among the parties with respect to the subject matter hereof
and supersede all prior agreements and understandings, both written and oral, among the parties with respect to the subject matter hereof. If and to the extent that any provision of this Agreement is inconsistent or conflicts with the Merger
Agreement, this Agreement shall govern and be controlling. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.11. <U>No Fiduciary Obligations</U>. Each of Parent and the Rights Agent acknowledges and
agrees that the other party, its affiliates and their respective officers, directors and controlling Persons do not owe any fiduciary duties to the first party or any of its respective affiliates, officers, directors or controlling Persons or to any
Holder. The only obligations of Parent and the Rights Agent to each other and their affiliates and their respective officers, directors and controlling Persons and to any Holder arising out of this Agreement are the contractual obligations expressly
set forth in this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.12. <U>Confidentiality</U>. The Rights Agent and Parent agree that all books, records, information and
data pertaining to the business of the other party, including, inter alia, personal, <FONT STYLE="white-space:nowrap">non-public</FONT> Holder information, which are exchanged or received pursuant to the negotiation or the carrying out of this
Agreement shall remain confidential, and shall not be voluntarily disclosed to any other person, except as may be required by a valid order of an arbitration panel, court or governmental body of competent jurisdiction or is otherwise required by law
or regulation, including SEC or Nasdaq rules and regulations, or pursuant to subpoenas from state or federal government authorities (e.g., in divorce and criminal actions). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.13. <U>Counterparts</U>. This Agreement may be executed in one or more counterparts, all of which shall be considered one and the same
agreement and shall become effective when one or more counterparts have been signed by each of the parties and delivered to the other party, it being understood that all parties need not sign the same counterpart. Delivery of an executed counterpart
of a signature page to this Agreement by facsimile or other electronic transmission, including by <FONT STYLE="white-space:nowrap">e-mail</FONT> attachment, shall be effective as delivery of a manually executed counterpart of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>REMAINDER OF PAGE INTENTIONALLY LEFT BLANK</I>] </P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, each of the parties has caused this Agreement to be executed on its
behalf by its duly authorized officers as of the day and year first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>JOHNSON&nbsp;&amp; JOHNSON</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Marc Larkins</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3">Name: Marc Larkins</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Title: Secretary</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>AMERICAN STOCK TRANSFER&nbsp;&amp; TRUST COMPANY, LLC</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Michael Legregin</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3">Name: Michael Legregin</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Title: Senior Vice President, Corporate Actions Relationship Management&nbsp;&amp; Operations</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature Page to Contingent Value Rights Agreement</I>] </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>EXHIBIT A </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Products and Product Pipeline </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Impella 2.5,
Impella CP, Impella RP, Impella 5.0, Impella LD, Impella 5.5, SmartAssist, Impella Connect, Impella XR Sheath, Automated Impella Controller (AIC), Impella BTR, Impella ECP, Impella Apto, Breethe <FONT STYLE="white-space:nowrap">Oxy-1</FONT> System
and PreCARDIA and, in each case, any related accessories or ancillary components </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>ANNEX A </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Budgeted Amounts </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">1. STEMI
Recommendation Milestone and FDA Approval Milestone: $37,682,000 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">2. HRPCI Milestone: $81,495,200 </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">3. Cardiogenic Shock Milestone: $39,800,000 </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>3
<FILENAME>d428734dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Johnson&nbsp;&amp; Johnson Completes Acquisition of Abiomed </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Broadens MedTech Portfolio with World Leading Solutions for Heart Recovery </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Strengthens Position in High-Growth MedTech Segments </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NEW BRUNSWICK, N.J. &#150; December 22, 2022</B> &#150; Johnson&nbsp;&amp; Johnson (NYSE: JNJ), the world&#146;s largest, most diversified healthcare
products company, today announced it has completed its acquisition of Abiomed, Inc. Abiomed is now part of Johnson&nbsp;&amp; Johnson and will operate as a standalone business within Johnson&nbsp;&amp; Johnson&#146;s MedTech segment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;We are excited to officially welcome the talented Abiomed team to Johnson&nbsp;&amp; Johnson. Their patient-first philosophy aligns with Our Credo and
Our Purpose to change the future of health for humanity,&#148; said Joaquin Duato, Chief Executive Officer of Johnson&nbsp;&amp; Johnson. &#147;This acquisition marks another important step on Johnson&nbsp;&amp; Johnson&#146;s path to accelerating
growth in our MedTech business and delivering innovative medical technologies to more people around the world.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ashley McEvoy, Executive Vice
President and Worldwide Chairman of MedTech at Johnson&nbsp;&amp; Johnson, added, &#147;The completion of this acquisition allows Johnson&nbsp;&amp; Johnson MedTech to expand our portfolio in the high growth cardiovascular markets, adding solutions
for heart recovery to our global market leading Biosense Webster electrophysiology business. Fueled by Johnson&nbsp;&amp; Johnson&#146;s global scale and commercial and clinical strength, we are excited to explore the opportunities and possibilities
ahead to reach even more patients with critical unmet need.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Johnson&nbsp;&amp; Johnson&#146;s tender offer for all outstanding shares of Abiomed
for an upfront payment of $380.00 per share in cash, corresponding to an enterprise value of approximately $16.6&nbsp;billion, which includes cash acquired, expired at 11:59 p.m., New York City time, on December&nbsp;21, 2022. Abiomed shareholders
will also receive a <FONT STYLE="white-space:nowrap">non-tradeable</FONT> contingent value right (&#147;CVR&#148;) entitling the holder to receive up to $35.00 per share in cash if certain commercial and clinical milestones are achieved. American
Stock Transfer&nbsp;&amp; Trust Company, LLC, the depositary for the tender offer, has advised Johnson&nbsp;&amp; Johnson that approximately 25,759,195 shares of Abiomed common stock were validly tendered and not properly withdrawn in the tender
offer, representing approximately 57.1% of the then-outstanding shares of Abiomed&#146;s common stock. All of the conditions to the tender offer have been satisfied, and on December&nbsp;22, 2022, Athos Merger Sub, Inc. (&#147;Purchaser&#148;), a
wholly-owned subsidiary of Johnson&nbsp;&amp; Johnson, accepted for payment, and will as promptly as practicable pay for, all shares validly tendered and not properly withdrawn in the tender offer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The acquisition was completed on December&nbsp;22, 2022 through a merger of Purchaser with and into Abiomed in accordance with Section&nbsp;251(h) of the
General Corporation Law of the State of Delaware without a vote of Abiomed stockholders. In connection with the merger, shares of Abiomed that were not tendered in the tender offer were acquired by Johnson&nbsp;&amp; Johnson and converted into the
right to receive $380.00 per share in cash plus a CVR. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The transaction will not have a material impact on financial results for 2022. As previously
announced, the transaction will accelerate pro forma MedTech and Johnson&nbsp;&amp; Johnson enterprise revenue growth. It is also expected to be slightly dilutive to neutral to adjusted earnings per share in the first year, considering the impact of
financing, and then accretive by approximately $0.05 in 2024, and increasingly accretive thereafter. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the completion of the
transaction, Abiomed&#146;s common stock ceased trading on NASDAQ. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Johnson&nbsp;&amp; Johnson </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At Johnson&nbsp;&amp; Johnson, we believe good health is the foundation of vibrant lives, thriving communities and forward progress. That&#146;s why for more
than 135 years, we have aimed to keep people well at every age and every stage of life. Today, as the world&#146;s largest and most broadly-based health care company, we are committed to using our reach and size for good. We strive to improve access
and affordability, create healthier communities, and put a healthy mind, body and environment within reach of everyone, everywhere. We are blending our heart, science and ingenuity to profoundly change the trajectory of health for humanity. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Cautionary Statement Regarding Forward-Looking Statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release contains forward-looking statements regarding the acquisition of Abiomed, Inc. The reader is cautioned not to rely on these forward-looking
statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and
projections of Abiomed, Inc. or Johnson&nbsp;&amp; Johnson. Risks and uncertainties include, but are not limited to: the potential that the expected benefits and opportunities of the acquisition may not be realized or may take longer to realize than
expected; challenges inherent in product research and development, including uncertainty of clinical success and obtaining regulatory approvals; uncertainty of commercial success for new products; manufacturing difficulties and delays; product
efficacy or safety concerns resulting in product recalls or regulatory action; economic conditions, including currency exchange and interest rate fluctuations; the risks associated with global operations; competition, including technological
advances, new products and patents attained by competitors; challenges to patents; changes to applicable laws and regulations, including tax laws and global health care reforms; adverse litigation or government action; changes in behavior and
spending patterns or financial distress of purchasers of health care services and products; and trends toward health care cost containment. In addition, there will be risks and uncertainties related to the ability of the Johnson&nbsp;&amp; Johnson
family of companies to successfully integrate the products and employees/operations and clinical work of Abiomed, Inc., as well as the ability to ensure continued performance or market growth of Abiomed Inc.&#146;s products. A further list and
descriptions of these risks, uncertainties and other factors can be found in Johnson&nbsp;&amp; Johnson&#146;s Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the fiscal year ended January&nbsp;2, 2022, including in the
sections captioned &#147;Cautionary Note Regarding Forward-Looking Statements&#148; and &#147;Item 1A. Risk Factors,&#148; and in Johnson&nbsp;&amp; Johnson&#146;s subsequent Quarterly Reports on Form <FONT STYLE="white-space:nowrap">10-Q,</FONT>
and other filings by Johnson&nbsp;&amp; Johnson with the SEC. Copies of these filings are available online at
www<FONT STYLE="font-family:Times New Roman; font-size:1pt" COLOR="#ff4338">.</FONT><FONT STYLE="font-family:Times New Roman; font-size:10pt">.sec.gov, at www.jnj.com or on request from Johnson&nbsp;&amp; Johnson. Neither Johnson&nbsp;&amp; Johnson
nor Abiomed, Inc. undertakes to update any forward-looking statement as a result of new information or future events or developments, except as required by law. </FONT></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Johnson&nbsp;&amp; Johnson: </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Press Contacts
</I></B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Jake Sargent </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">jsargen3@its.jnj.com </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Rachel Hooper </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">rhooper@its.jnj.com </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Investor Contacts </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Jessica Moore </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">732-524-2955</FONT></FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sarah Wood </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">732-524-2617</FONT></FONT> </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>jnj-20221222.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20221108.6 -->
<!-- Creation date: 12/23/2022 2:12:43 AM Eastern Time -->
<!-- Copyright (c) 2022 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema
  xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
  xmlns:num="http://www.xbrl.org/dtr/type/numeric"
  xmlns:us-types="http://fasb.org/us-types/2022"
  xmlns:jnj="http://www.jnj.com/20221222"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  attributeFormDefault="unqualified"
  elementFormDefault="qualified"
  targetNamespace="http://www.jnj.com/20221222"
  xmlns:xsd="http://www.w3.org/2001/XMLSchema">
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd" namespace="http://xbrl.sec.gov/dei/2022" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2022/naics-2022.xsd" namespace="http://xbrl.sec.gov/naics/2022" />
    <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
    <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd" namespace="http://fasb.org/us-gaap/2022" />
    <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd" namespace="http://fasb.org/us-types/2022" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="jnj-20221222_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="jnj-20221222_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="jnj-20221222_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:title="Definition Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.jnj.com//20221222/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="jnj_DocumentAndEntityInformationTable" name="DocumentAndEntityInformationTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="jnj_DocumentAndEntityInformationLineItems" name="DocumentAndEntityInformationLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="jnj_A0.650NotesDue2024Member" name="A0.650NotesDue2024Member" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="jnj_A5.50NotesDue2024Member" name="A5.50NotesDue2024Member" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="jnj_A1.150NotesDue2028Member" name="A1.150NotesDue2028Member" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="jnj_A1.650NotesDue2035Member" name="A1.650NotesDue2035Member" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>5
<FILENAME>jnj-20221222_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20221108.6 -->
<!-- Creation date: 12/23/2022 2:12:46 AM Eastern Time -->
<!-- Copyright (c) 2022 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
  <link:roleRef roleURI="http://www.jnj.com//20221222/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="jnj-20221222.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.jnj.com//20221222/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="jnj-20221222.xsd#jnj_DocumentAndEntityInformationTable" xlink:type="locator" xlink:label="jnj_DocumentAndEntityInformationTable" />
    <link:loc xlink:href="jnj-20221222.xsd#jnj_DocumentAndEntityInformationLineItems" xlink:type="locator" xlink:label="jnj_DocumentAndEntityInformationLineItems" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="jnj-20221222.xsd#jnj_A0.650NotesDue2024Member" xlink:type="locator" xlink:label="jnj_A0.650NotesDue2024Member" />
    <link:loc xlink:href="jnj-20221222.xsd#jnj_A5.50NotesDue2024Member" xlink:type="locator" xlink:label="jnj_A5.50NotesDue2024Member" />
    <link:loc xlink:href="jnj-20221222.xsd#jnj_A1.150NotesDue2028Member" xlink:type="locator" xlink:label="jnj_A1.150NotesDue2028Member" />
    <link:loc xlink:href="jnj-20221222.xsd#jnj_A1.650NotesDue2035Member" xlink:type="locator" xlink:label="jnj_A1.650NotesDue2035Member" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="jnj_DocumentAndEntityInformationLineItems" xlink:to="jnj_DocumentAndEntityInformationTable" order="1" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="jnj_DocumentAndEntityInformationTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="23" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_2" order="23.0001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonStockMember" order="24" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="jnj_A0.650NotesDue2024Member" order="25" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="jnj_A5.50NotesDue2024Member" order="26" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="jnj_A1.150NotesDue2028Member" order="27" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="jnj_A1.650NotesDue2035Member" order="28" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="jnj_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" order="30.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="jnj_DocumentAndEntityInformationLineItems" xlink:to="dei_AmendmentFlag" order="31.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="jnj_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="32.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="jnj_DocumentAndEntityInformationLineItems" xlink:to="dei_DocumentType" order="36.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="jnj_DocumentAndEntityInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" order="37.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="jnj_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityRegistrantName" order="38.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="jnj_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="39.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="jnj_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityFileNumber" order="40.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="jnj_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" order="41.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="jnj_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" order="42.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="jnj_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" order="43.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="jnj_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" order="44.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="jnj_DocumentAndEntityInformationLineItems" xlink:to="dei_CityAreaCode" order="45.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="jnj_DocumentAndEntityInformationLineItems" xlink:to="dei_LocalPhoneNumber" order="46.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="jnj_DocumentAndEntityInformationLineItems" xlink:to="dei_WrittenCommunications" order="47.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="jnj_DocumentAndEntityInformationLineItems" xlink:to="dei_SolicitingMaterial" order="48.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="jnj_DocumentAndEntityInformationLineItems" xlink:to="dei_PreCommencementTenderOffer" order="49.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="jnj_DocumentAndEntityInformationLineItems" xlink:to="dei_PreCommencementIssuerTenderOffer" order="50.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="jnj_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="51.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="jnj_DocumentAndEntityInformationLineItems" xlink:to="dei_Security12bTitle" order="52.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="jnj_DocumentAndEntityInformationLineItems" xlink:to="dei_TradingSymbol" order="53.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="jnj_DocumentAndEntityInformationLineItems" xlink:to="dei_SecurityExchangeName" order="54.001" priority="2" use="optional" />
  </link:definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>6
<FILENAME>jnj-20221222_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20221108.6 -->
<!-- Creation date: 12/23/2022 2:12:43 AM Eastern Time -->
<!-- Copyright (c) 2022 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security 12b Title</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security 12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:loc xlink:href="jnj-20221222.xsd#jnj_DocumentAndEntityInformationTable" xlink:type="locator" xlink:label="jnj_DocumentAndEntityInformationTable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="jnj_DocumentAndEntityInformationTable" xlink:to="jnj_DocumentAndEntityInformationTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="jnj_DocumentAndEntityInformationTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document And Entity Information [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="jnj_DocumentAndEntityInformationTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document And Entity Information [Table]</link:label>
    <link:loc xlink:href="jnj-20221222.xsd#jnj_DocumentAndEntityInformationLineItems" xlink:type="locator" xlink:label="jnj_DocumentAndEntityInformationLineItems" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="jnj_DocumentAndEntityInformationLineItems" xlink:to="jnj_DocumentAndEntityInformationLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="jnj_DocumentAndEntityInformationLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document And Entity Information [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="jnj_DocumentAndEntityInformationLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document And Entity Information [Line Items]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock [Member]</link:label>
    <link:loc xlink:href="jnj-20221222.xsd#jnj_A0.650NotesDue2024Member" xlink:type="locator" xlink:label="jnj_A0.650NotesDue2024Member" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="jnj_A0.650NotesDue2024Member" xlink:to="jnj_A0.650NotesDue2024Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="jnj_A0.650NotesDue2024Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">A 0.650 Notes Due 2024 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="jnj_A0.650NotesDue2024Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">A 0.650 Notes Due 2024 [Member]</link:label>
    <link:loc xlink:href="jnj-20221222.xsd#jnj_A5.50NotesDue2024Member" xlink:type="locator" xlink:label="jnj_A5.50NotesDue2024Member" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="jnj_A5.50NotesDue2024Member" xlink:to="jnj_A5.50NotesDue2024Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="jnj_A5.50NotesDue2024Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">A 5.50 Notes Due 2024 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="jnj_A5.50NotesDue2024Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">A 5.50 Notes Due 2024 [Member]</link:label>
    <link:loc xlink:href="jnj-20221222.xsd#jnj_A1.150NotesDue2028Member" xlink:type="locator" xlink:label="jnj_A1.150NotesDue2028Member" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="jnj_A1.150NotesDue2028Member" xlink:to="jnj_A1.150NotesDue2028Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="jnj_A1.150NotesDue2028Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">A 1.150 Notes Due 2028 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="jnj_A1.150NotesDue2028Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">A 1.150 Notes Due 2028 [Member]</link:label>
    <link:loc xlink:href="jnj-20221222.xsd#jnj_A1.650NotesDue2035Member" xlink:type="locator" xlink:label="jnj_A1.650NotesDue2035Member" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="jnj_A1.650NotesDue2035Member" xlink:to="jnj_A1.650NotesDue2035Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="jnj_A1.650NotesDue2035Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">A 1.650 Notes Due 2035 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="jnj_A1.650NotesDue2035Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">A 1.650 Notes Due 2035 [Member]</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>7
<FILENAME>jnj-20221222_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20221108.6 -->
<!-- Creation date: 12/23/2022 2:12:44 AM Eastern Time -->
<!-- Copyright (c) 2022 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
    xmlns:link="http://www.xbrl.org/2003/linkbase"
    xmlns:xlink="http://www.w3.org/1999/xlink"
    xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
    xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
    xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.jnj.com//20221222/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="jnj-20221222.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.jnj.com//20221222/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:loc xlink:href="jnj-20221222.xsd#jnj_DocumentAndEntityInformationTable" xlink:type="locator" xlink:label="jnj_DocumentAndEntityInformationTable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="jnj_DocumentAndEntityInformationTable" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="jnj-20221222.xsd#jnj_DocumentAndEntityInformationLineItems" xlink:type="locator" xlink:label="jnj_DocumentAndEntityInformationLineItems" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="jnj_DocumentAndEntityInformationTable" xlink:to="jnj_DocumentAndEntityInformationLineItems" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="jnj_DocumentAndEntityInformationTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonStockMember" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="jnj-20221222.xsd#jnj_A0.650NotesDue2024Member" xlink:type="locator" xlink:label="jnj_A0.650NotesDue2024Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="jnj_A0.650NotesDue2024Member" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="jnj-20221222.xsd#jnj_A5.50NotesDue2024Member" xlink:type="locator" xlink:label="jnj_A5.50NotesDue2024Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="jnj_A5.50NotesDue2024Member" order="26" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="jnj-20221222.xsd#jnj_A1.150NotesDue2028Member" xlink:type="locator" xlink:label="jnj_A1.150NotesDue2028Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="jnj_A1.150NotesDue2028Member" order="27" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="jnj-20221222.xsd#jnj_A1.650NotesDue2035Member" xlink:type="locator" xlink:label="jnj_A1.650NotesDue2035Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="jnj_A1.650NotesDue2035Member" order="28" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="jnj_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" order="30.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="jnj_DocumentAndEntityInformationLineItems" xlink:to="dei_AmendmentFlag" order="31.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="jnj_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="32.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="jnj_DocumentAndEntityInformationLineItems" xlink:to="dei_DocumentType" order="36.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="jnj_DocumentAndEntityInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" order="37.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="jnj_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityRegistrantName" order="38.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="jnj_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="39.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="jnj_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityFileNumber" order="40.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="jnj_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" order="41.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="jnj_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" order="42.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="jnj_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" order="43.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="jnj_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" order="44.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="jnj_DocumentAndEntityInformationLineItems" xlink:to="dei_CityAreaCode" order="45.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="jnj_DocumentAndEntityInformationLineItems" xlink:to="dei_LocalPhoneNumber" order="46.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="jnj_DocumentAndEntityInformationLineItems" xlink:to="dei_WrittenCommunications" order="47.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="jnj_DocumentAndEntityInformationLineItems" xlink:to="dei_SolicitingMaterial" order="48.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="jnj_DocumentAndEntityInformationLineItems" xlink:to="dei_PreCommencementTenderOffer" order="49.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="jnj_DocumentAndEntityInformationLineItems" xlink:to="dei_PreCommencementIssuerTenderOffer" order="50.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="jnj_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="51.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="jnj_DocumentAndEntityInformationLineItems" xlink:to="dei_Security12bTitle" order="52.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="jnj_DocumentAndEntityInformationLineItems" xlink:to="dei_TradingSymbol" order="53.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="jnj_DocumentAndEntityInformationLineItems" xlink:to="dei_SecurityExchangeName" order="54.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139848861900288">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Dec. 22, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_DocumentAndEntityInformationLineItems', window );"><strong>Document And Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">One Johnson & Johnson Plaza<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000200406<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 22,  2022<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Johnson&#160;& Johnson<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">NJ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">1-3215<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">22-1024240<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">New Brunswick<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NJ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">08933<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">732<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">524-0400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre Commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre Commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_DocumentAndEntityInformationLineItems', window );"><strong>Document And Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Common Stock, Par Value $1.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">JNJ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=jnj_A0.650NotesDue2024Member', window );">A 0.650 Notes Due 2024 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_DocumentAndEntityInformationLineItems', window );"><strong>Document And Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">0.650% Notes Due May 2024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">JNJ24C<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=jnj_A5.50NotesDue2024Member', window );">A 5.50 Notes Due 2024 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_DocumentAndEntityInformationLineItems', window );"><strong>Document And Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">5.50% Notes Due November 2024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">JNJ24BP<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=jnj_A1.150NotesDue2028Member', window );">A 1.150 Notes Due 2028 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_DocumentAndEntityInformationLineItems', window );"><strong>Document And Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">1.150% Notes Due November 2028<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">JNJ28<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=jnj_A1.650NotesDue2035Member', window );">A 1.650 Notes Due 2035 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_DocumentAndEntityInformationLineItems', window );"><strong>Document And Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">1.650% Notes Due May 2035<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">JNJ35<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_DocumentAndEntityInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_DocumentAndEntityInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=jnj_A0.650NotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=jnj_A0.650NotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=jnj_A5.50NotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=jnj_A5.50NotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=jnj_A1.150NotesDue2028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=jnj_A1.150NotesDue2028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=jnj_A1.650NotesDue2035Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=jnj_A1.650NotesDue2035Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>d428734d8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:jnj="http://www.jnj.com/20221222"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="jnj-20221222.xsd" xlink:type="simple"/>
    <context id="duration_2022-12-22_to_2022-12-22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
        </entity>
        <period>
            <startDate>2022-12-22</startDate>
            <endDate>2022-12-22</endDate>
        </period>
    </context>
    <context id="duration_2022-12-22_to_2022-12-22_us-gaap-StatementClassOfStockAxis_us-gaap-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-22</startDate>
            <endDate>2022-12-22</endDate>
        </period>
    </context>
    <context id="duration_2022-12-22_to_2022-12-22_us-gaap-StatementClassOfStockAxis_jnj-A0.650NotesDue2024Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">jnj:A0.650NotesDue2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-22</startDate>
            <endDate>2022-12-22</endDate>
        </period>
    </context>
    <context id="duration_2022-12-22_to_2022-12-22_us-gaap-StatementClassOfStockAxis_jnj-A5.50NotesDue2024Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">jnj:A5.50NotesDue2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-22</startDate>
            <endDate>2022-12-22</endDate>
        </period>
    </context>
    <context id="duration_2022-12-22_to_2022-12-22_us-gaap-StatementClassOfStockAxis_jnj-A1.150NotesDue2028Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">jnj:A1.150NotesDue2028Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-22</startDate>
            <endDate>2022-12-22</endDate>
        </period>
    </context>
    <context id="duration_2022-12-22_to_2022-12-22_us-gaap-StatementClassOfStockAxis_jnj-A1.650NotesDue2035Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">jnj:A1.650NotesDue2035Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-22</startDate>
            <endDate>2022-12-22</endDate>
        </period>
    </context>
    <dei:EntityAddressAddressLine1
      contextRef="duration_2022-12-22_to_2022-12-22"
      id="Hidden_dei_EntityAddressAddressLine1">One Johnson &amp; Johnson Plaza</dei:EntityAddressAddressLine1>
    <dei:AmendmentFlag contextRef="duration_2022-12-22_to_2022-12-22">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="duration_2022-12-22_to_2022-12-22"
      id="Hidden_dei_EntityCentralIndexKey">0000200406</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="duration_2022-12-22_to_2022-12-22">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="duration_2022-12-22_to_2022-12-22">2022-12-22</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="duration_2022-12-22_to_2022-12-22">Johnson&#160;&amp; Johnson</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="duration_2022-12-22_to_2022-12-22">NJ</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="duration_2022-12-22_to_2022-12-22">1-3215</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="duration_2022-12-22_to_2022-12-22">22-1024240</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressCityOrTown contextRef="duration_2022-12-22_to_2022-12-22">New Brunswick</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="duration_2022-12-22_to_2022-12-22">NJ</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="duration_2022-12-22_to_2022-12-22">08933</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="duration_2022-12-22_to_2022-12-22">732</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="duration_2022-12-22_to_2022-12-22">524-0400</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="duration_2022-12-22_to_2022-12-22">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="duration_2022-12-22_to_2022-12-22">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="duration_2022-12-22_to_2022-12-22">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="duration_2022-12-22_to_2022-12-22">false</dei:PreCommencementIssuerTenderOffer>
    <dei:EntityEmergingGrowthCompany contextRef="duration_2022-12-22_to_2022-12-22">false</dei:EntityEmergingGrowthCompany>
    <dei:Security12bTitle contextRef="duration_2022-12-22_to_2022-12-22_us-gaap-StatementClassOfStockAxis_us-gaap-CommonStockMember">Common Stock, Par Value $1.00</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="duration_2022-12-22_to_2022-12-22_us-gaap-StatementClassOfStockAxis_us-gaap-CommonStockMember">JNJ</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="duration_2022-12-22_to_2022-12-22_us-gaap-StatementClassOfStockAxis_us-gaap-CommonStockMember">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle contextRef="duration_2022-12-22_to_2022-12-22_us-gaap-StatementClassOfStockAxis_jnj-A0.650NotesDue2024Member">0.650% Notes Due May 2024</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="duration_2022-12-22_to_2022-12-22_us-gaap-StatementClassOfStockAxis_jnj-A0.650NotesDue2024Member">JNJ24C</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="duration_2022-12-22_to_2022-12-22_us-gaap-StatementClassOfStockAxis_jnj-A0.650NotesDue2024Member">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle contextRef="duration_2022-12-22_to_2022-12-22_us-gaap-StatementClassOfStockAxis_jnj-A5.50NotesDue2024Member">5.50% Notes Due November 2024</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="duration_2022-12-22_to_2022-12-22_us-gaap-StatementClassOfStockAxis_jnj-A5.50NotesDue2024Member">JNJ24BP</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="duration_2022-12-22_to_2022-12-22_us-gaap-StatementClassOfStockAxis_jnj-A5.50NotesDue2024Member">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle contextRef="duration_2022-12-22_to_2022-12-22_us-gaap-StatementClassOfStockAxis_jnj-A1.150NotesDue2028Member">1.150% Notes Due November 2028</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="duration_2022-12-22_to_2022-12-22_us-gaap-StatementClassOfStockAxis_jnj-A1.150NotesDue2028Member">JNJ28</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="duration_2022-12-22_to_2022-12-22_us-gaap-StatementClassOfStockAxis_jnj-A1.150NotesDue2028Member">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle contextRef="duration_2022-12-22_to_2022-12-22_us-gaap-StatementClassOfStockAxis_jnj-A1.650NotesDue2035Member">1.650% Notes Due May 2035</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="duration_2022-12-22_to_2022-12-22_us-gaap-StatementClassOfStockAxis_jnj-A1.650NotesDue2035Member">JNJ35</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="duration_2022-12-22_to_2022-12-22_us-gaap-StatementClassOfStockAxis_jnj-A1.650NotesDue2035Member">NYSE</dei:SecurityExchangeName>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>10
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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M    $               @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0
M   ( /.#EE6@$ O5[0   "L"   1              "  :\   !D;V-0<F]P
M<R]C;W)E+GAM;%!+ 0(4 Q0    ( /.#EE697)PC$ 8  )PG   3
M      "  <L!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @ \X.6
M512GXVR*!0  Y1X  !@              ("!# @  'AL+W=O<FMS:&5E=',O
M<VAE970Q+GAM;%!+ 0(4 Q0    ( /.#EE6?H!OPL0(  .(,   -
M      "  <P-  !X;"]S='EL97,N>&UL4$L! A0#%     @ \X.659>*NQS
M    $P(   L              ( !J!   %]R96QS+RYR96QS4$L! A0#%
M  @ \X.651PX9>H_ 0  / (   \              ( !D1$  'AL+W=O<FMB
M;V]K+GAM;%!+ 0(4 Q0    ( /.#EE4D'INBK0   /@!   :
M  "  ?T2  !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    (
M /.#EE5ED'F2&0$  ,\#   3              "  >(3  !;0V]N=&5N=%]4
?>7!E<UTN>&UL4$L%!@     )  D /@(  "P5      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>6</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>5</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="d428734d8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com//20221222/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 1 fact(s) appearing in ix:hidden were eligible for transformation: dei:EntityAddressAddressLine1 -  d428734d8k.htm 7</Log>
  </Logs>
  <InputFiles>
    <File doctype="8-K" original="d428734d8k.htm">d428734d8k.htm</File>
    <File>d428734dex101.htm</File>
    <File>d428734dex991.htm</File>
    <File>jnj-20221222.xsd</File>
    <File>jnj-20221222_def.xml</File>
    <File>jnj-20221222_lab.xml</File>
    <File>jnj-20221222_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="34">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>16
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "d428734d8k.htm": {
   "axisCustom": 0,
   "axisStandard": 1,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2022": 34
   },
   "contextCount": 6,
   "dts": {
    "definitionLink": {
     "local": [
      "jnj-20221222_def.xml"
     ]
    },
    "inline": {
     "local": [
      "d428734d8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "jnj-20221222_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "jnj-20221222_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "jnj-20221222.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd",
      "https://xbrl.sec.gov/naics/2022/naics-2022.xsd"
     ]
    }
   },
   "elementCount": 32,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2022": 3,
    "total": 3
   },
   "keyCustom": 0,
   "keyStandard": 22,
   "memberCustom": 4,
   "memberStandard": 1,
   "nsprefix": "jnj",
   "nsuri": "http://www.jnj.com/20221222",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d428734d8k.htm",
      "contextRef": "duration_2022-12-22_to_2022-12-22",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Document and Entity Information",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.jnj.com//20221222/taxonomy/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d428734d8k.htm",
      "contextRef": "duration_2022-12-22_to_2022-12-22",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 5,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.jnj.com//20221222/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.jnj.com//20221222/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.jnj.com//20221222/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.jnj.com//20221222/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.jnj.com//20221222/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.jnj.com//20221222/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.jnj.com//20221222/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.jnj.com//20221222/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.jnj.com//20221222/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.jnj.com//20221222/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.jnj.com//20221222/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation State Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.jnj.com//20221222/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.jnj.com//20221222/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.jnj.com//20221222/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.jnj.com//20221222/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre Commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.jnj.com//20221222/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre Commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.jnj.com//20221222/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Security 12b Title",
        "terseLabel": "Security 12b Title"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.jnj.com//20221222/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.jnj.com//20221222/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.jnj.com//20221222/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.jnj.com//20221222/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.jnj.com//20221222/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "jnj_A0.650NotesDue2024Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "A 0.650 Notes Due 2024 [Member]",
        "terseLabel": "A 0.650 Notes Due 2024 [Member]"
       }
      }
     },
     "localname": "A0.650NotesDue2024Member",
     "nsuri": "http://www.jnj.com/20221222",
     "presentation": [
      "http://www.jnj.com//20221222/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A1.150NotesDue2028Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "A 1.150 Notes Due 2028 [Member]",
        "terseLabel": "A 1.150 Notes Due 2028 [Member]"
       }
      }
     },
     "localname": "A1.150NotesDue2028Member",
     "nsuri": "http://www.jnj.com/20221222",
     "presentation": [
      "http://www.jnj.com//20221222/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A1.650NotesDue2035Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "A 1.650 Notes Due 2035 [Member]",
        "terseLabel": "A 1.650 Notes Due 2035 [Member]"
       }
      }
     },
     "localname": "A1.650NotesDue2035Member",
     "nsuri": "http://www.jnj.com/20221222",
     "presentation": [
      "http://www.jnj.com//20221222/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A5.50NotesDue2024Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "A 5.50 Notes Due 2024 [Member]",
        "terseLabel": "A 5.50 Notes Due 2024 [Member]"
       }
      }
     },
     "localname": "A5.50NotesDue2024Member",
     "nsuri": "http://www.jnj.com/20221222",
     "presentation": [
      "http://www.jnj.com//20221222/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_DocumentAndEntityInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document And Entity Information [Line Items]",
        "terseLabel": "Document And Entity Information [Line Items]"
       }
      }
     },
     "localname": "DocumentAndEntityInformationLineItems",
     "nsuri": "http://www.jnj.com/20221222",
     "presentation": [
      "http://www.jnj.com//20221222/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stringItemType"
    },
    "jnj_DocumentAndEntityInformationTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document And Entity Information [Table]",
        "terseLabel": "Document And Entity Information [Table]"
       }
      }
     },
     "localname": "DocumentAndEntityInformationTable",
     "nsuri": "http://www.jnj.com/20221222",
     "presentation": [
      "http://www.jnj.com//20221222/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com//20221222/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock [Member]"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com//20221222/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com//20221222/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>17
<FILENAME>0001193125-22-311072-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-22-311072-xbrl.zip
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M7W[8<C;G[X:CE':G6TU*QX@";?8A ?6%0Y$6*F5'%N"&Z%+'<9PUEV0G%(<
M2VR[G>EK2%AK"G<R#29@NL3$4U]@VE0$*@2W57[>/2B].6S0;B'[^;!>VCO:
M+S5J->KVY]VCTJ'92K1SE _"&Y1@IH]T/$S!7HF* 0/)D-MJIX1I6?\V^'&0
MCX \<;>RKP^\REU2-1(OKI@[+J(N]T>P#4^4H 0A&5&VP,3TF6UIT(3GZ= 1
M.^CEE>S=6"KP-#IY&SXB5V.F8"@02IPQ? UQ7&Q"K!]XU MPI/""/HY?8CJZ
M#J*L1&")$(_6L0X/OJFX/F4CM[L+$& :E)F9THLJ+;AF6Y VZQ[!&DC3,+9A
M/?$T=$R "YGLZ2N9O<$.@FO6!9\D\HM$B(< T[D+'1 PB#1H(NA:A/SSY)9D
M/7T]3SO'_ 1I& 6R*#^Q(-EWS.^\J=4GW%S0J6#]0"F)M@5MO/K(,0;Y*2S)
M-I[=(B62T,=/.&AZ8:8+[GYB' 73CZ@]+HG-N$&L)5DV!40J*3@+D]9 4?I8
M EB 7B;>WI(<;I;ISL(&N!;)-F7!"*;_?V5Z2&5$0B_9/#RC3T8W0P' GC #
MNX+D!=!N#QMW0$,%(9"#"O3)'1I)F$&$N7N8Y("P6.Z8G(-):83(=S9I4R)9
MW.&.-</@%"R(#U2L5!Q2$B&M8": /6$!&>E-TSS%9#'6DK=[W!6KI\L[BKV'
MXCY @\<5(&)D/WM:=UX1N8$P!!.'=+\G0-X6QEN(M,""%?M/#%R8O>D/HQ8@
MNP9HL(2B T@E'.II=V)D5-#6A6-B6I03] ?I DO<5O<P^1'/J^O*MHQ8O5:I
MZ_[@:2L.0X3V1M]!"I.9^[AS,Q&9W!T$PR$M2#\WA8H-'&Z"D]]8<'*IQ12-
MUUQ,T=+,;63"J0/2VQSM!W+M3"K0'3)YJI2(U L454Q+$Z<T!UNE;'(;]FV2
M<YH!;D]$Q5Q^G6,-L\*<7;)@2&^-2Q'7"=MHS&)B WI%VO &P_6PELMO+3%?
M1.D.E.?!@V>GO"[H!ZDN.^WA08NCF:U>K%)C'U7R\Y.#,[G .FM>9PNGF;^+
M)L*"QAB9@%86!4G.DU*47R8[N30QURMC6FQKGRI9-;U*N#BTW8[G-&;<HOD)
M0B>H7R/YCN S 5%GP)/[D+I2QM)RI7&C!"7M@(UCYGIEV<@R6XFYI%6+F9(R
M=WA/GR:*QGR2"R1LEA^( !H8_G_&7#,0#6_9F,H2??RI1\!^$I%)X*-2!W#T
M(B#K[0@\7+)TD]*3D<ZI-YWA:#NS!_D#0:QGLFLOWKE:L+#$!]IV;,9JBLXN
M=S%F0%P%#^KUYOX1ZU=ZE5):3]*B$A)"TVA92]T2UP(8/,>!M>>,\RPB%FWD
MJR3NH,%H<SS9UO".]'5Y,YV,:Q-SVP/CNI,JQ5"C#;71O 'H_=+!_E&I?K2O
M)V)TS2,Z)\\N"2JE\I$R<3'F\R21..'=_8-*_1<KB."O7Q[5>5;49J%2,5Y]
M)H4>J\M!RJ(;I\69+WMQ#RMYM+0HRM(;UM])#GJFA"8 MX)K;WI",4V:<81Q
M#0>6UB4'3D<BLP?P-O;KV]UDH*1J[J/P10A<WLI4SWWBCPL1T=G'UJ>B:D-4
M(YP]!'B/JM$#;I#SPT;JWC*A7RI&,V&!"COUO*PDSI4>P4+@NK6%\,UE31(#
M#*D!A.XO*"X8  .W2?W<P-3/#7GM: J959^+#+.1^B&^TC6,Y 3#F[T^P@'#
MT;#$5&:\0E)>O43[D)3O:(67-8TS'#6AHFX8\%P]V;CJQGGH%D@LNZ)XWK>Q
M0DQO,/!S*A,UC*/F%A7-9C8CI!^3/-%&EXK#!TG$EZU"S7.["3V' FB;@DST
M_F)%M< '6MQ@=35=1);%<$F'QK5!EY5H$NQ_5VK9E]]0@H4ERTKKXOQZ+:1/
MD@Z+U,EVD,:9D^B](7V-",#1I++P3%5KF"XW?.X*CTC*_);>P1A2/<= IQ>W
M=?#5!)DQG.N;SXN5.$,/"41D_^ISG<DPBBPOI1>ZC C[L>N21V-F>\(@:[P,
MLX99<9$FM$@V,H;QCIC)RES$B=9QB;!#F*U(= 6(#EV @[%75+!<*ELKJ73U
M,D;+Q_'WFT:6N4%C $\!AV&HP!;&%OHUZ6S(HE_<8UE_F?=$J5BR-)-?_$W5
MXVA:^=0L@-T9XEPDE=Z,[Z->?&_/XKE]"P6\9ER#D?@622)B9V9,+MP$L=+!
M\/XVR.'%3DQ@5]3IL(#/*AWM,LPHXJPF!T\(M[N4,-$F7=VG-#N3WAB.%2PP
MA^=?>'L!2]<5Y<^!CS='9R^('8,8$FXH"3WM#20GL5N?*#<E,UMA"X>09?.(
MV1F*D61U3XGA]:42WDR],'T#,2Z(67J-#KJVA S0->!D7-'>9J/AF]MHV(CH
M645T7IZN3H *W+VDJ$'(P.+ (-U7)$^G-KB*HW+0&2=@GBE[1T/GN2,]$M21
M"1=@;)1K7 V'LI,3-9C>&M!>/K%SP6$^G,+XVY*2!,!!2:6^[AU$MPY!D8 >
M6E=[%,'(\B7=O8@26.I";JJ\-Y)V>9(67%B*4J,[J@WCV)=4$&<35E+&>(9A
M?'W[QQ*MXGG,QB5;A)D)E=B]#A>3WX]>K Y%VST LQ&:Q3 "2)E!F=_T<19*
MZR2*+%#(UN;9N 8Y!7A C[['GRC"/C(*[EQ'YI"-X;$VF?4;,;)<,8(1)M#
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MR!K>=DPB>@4!C;?5=N .X)=NU/-._A]02P,$%     @ \X.652D9J>\&9P
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MQB:[JD::[N:5"<=<B?0!J:+"J1QA>B47$'-<: S#P.0"1!9)45#V^\6,0%%
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MD*F2$VMBABHKL%8C+ZZ23"H*X^A/2DO'\<\0I6UL"(:I-5&0YL&D[I$(_E#
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MH?"G*YAGUNYCC6X*M#\RIV#ZN2!]K+89IBR<Z C#)@!O>6/UTC/@.7T3))
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M$"L8,DFJO"CYX%*YAN1PRA3E564*FY;0Z&&A)YL@C\$NAVS&)=9K.5QOY$?
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M\0G_UBV_IEY=)86E1IMH)%S.KADG[-LZS9:)[$7'+:4'O-86;%#\#@'1MS1
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ML<Y7L]^VMW))I_>'BM[,"L\-AJ4&TMF)2\ZT4HA2.(MY6W[\4N.%CYL"U(C
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M[S<O:7__A[OK'@&1!&^DKM]BF5'AU]$WW4 4H T,>%7C$^! Z60Z8Q^QD&;
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M!=A*'5:S&E&I.I%I'JTJ""%H<B&=>KDELS$*I>P-K"X5:L@ZZW'\OU)*HX#
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M /QK.A%->GW< 25R#@X8L>U$#0@MV"-^\T#.!2E$CDL1W-P6H5<+-Z7@+CS
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MZ2_Y;/K80/Q&-S4;W^*HIYUG=SOJCK$Q /?^Y!,>\A^[_A=02P,$%     @
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MXYH!7[IZ,@;2:*;N*1K6PSH[WTR_W^L-*/:"Q0Q#"R*X_'L'PIDGV!;M39Y
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MO3<O:*V]4J%?:7M^<4M=_ =02P,$%     @ \X.658>KU_XU"   1EX  !0
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M,C$R,C)?<')E+GAM;-6;77/B-A2&[W=F_X/JWK0SM8U-R";,LCN4)!VF^9K
MMIW>9(1] .W:$B.)!/Y])6.U&(QC[^XT*!<!;+U'Y]4CRY(P[S^NT@0] 1>$
MT9X3>"T' 8U83.BLYRR%BT5$B(.$Q#3&":/0<]8@G(\?WKYY_X/KHHNKX2UR
MT5S*A>CZ_O/SLQ=/"14L64H54G@12WWDNJ;\8/P)_;&IKHL>( $L *582.#H
MUR5)XF[8"L,@:)UYI]LR#EC'0S&6T$5!Z(=M7Y=$83<(NR<GJ'^#+K,P%(U)
M"MM:MEAS,IM+]%/T,\I$%XQ22!)8HRM",8T(3M#(I/P+&M+(0_TD00]:)E2>
M O@3Q%X>-2'T2U?_F^CLT=LW2/VIAJ0B.]IS='/DK;&:\,1C?*:R;;5](W*V
M-:L]T7,[DP3GY^=^=K987I"RTJJ"P/_KYGH4S2'%KH*@H$4[5:EL8OFO>CNY
MCK\Y:<H+TA59I&L696U?PQ8Z6$)_<DTQ5Q]R@]!M!]Y*Q,X'7>6F53E+X &F
M2+]^>A@6ZOQ,/V?=*0,?A&'H2[QBE*5K7Q?W+UBT3(%*\]JG\2651*Z'=,IX
MFIEP4-:>W3F':<]1$5T33&?RXX.*\]@DCEPOU"4A2+I(P$'^EI,%5[V&RJST
MM3I0$,!* HTA-F%T_M_?ZX<-RKR_LJC@W5RR&2<!D3=C3WX,)*M1O\E:)FL5
M]>%QP-0HT9\(R7$DB^X3W4$8-P<3/(&DYY2(_,J$]F"H X]5_L9XHAO]Y51J
M!BJFM\VOSZ-"-9A'I@KU=@]>L>OG)?P%YBJ>&\W5*&?44\[2TJ;*:V.UDV<\
M!MYSPL!!"TX85X74)P<MA<J-+71)G.AS, 7.(;[>-,W!K+.4U7 J("OYW>&I
M2P*&$E+Q/0!N!7LUB,UZ:PVP6Z8,W/!UX!:&BBD6DRR2FAW,,%YLQ@M(I#!'
M_ALX\@./(T4 M,]!@H6XFXXDB[[T5Z06_!I![(%>PTP.^Y4NY&]FO6WH@J68
MT":0R]2O1K=^]V75#LSUV[:5*4M31C-+-Y!.@#="NB]^=:(5G9159FY(GAS1
M;;;?\DX[K5LF05PL09T^J0^I6G_DG*J3-Z@ZQX2JXWT3J4-R&T =RMUP.CTF
M3H$7%+(]:PCJH-X&4@>3-ZC>'1>JP@#0[C1&=4!O!ZH#R1M49T<PY7AY=V$S
M<>['L6IDD;_H]4]0=Z>A(L#1+@[VE\#L13,YUG;+:[6.887P,MJ^LA_K)KA*
M\*PNSAV1?0AW#!AL@378-E8'R@''R9#&L/H=ULVNQCVQ?1@/&#$X0VMP&O=C
MU;QU*18U]L$KYF^8G5K'[!Y4KLIW?(%E8W@[8GLI[A@Q.-]9@W-C^0%F1&_R
M4WF+T]HTR[7VP2SW85B>6<9R2"/&%XQGGK--P@%;JEO%>L#BAFA?"&4KZ1=L
M&?#GEH&_(@G<+NNN,LMUMB+=]I#S.[%G-;+Q,,:K8:SLDRG9/-OP-3 /!K&5
M[$%#!K-MJY=\Z3Q0;^_XF#W7^B:J4FXKVA(K!JH]:YB"E>QF<L?O.7LB^BFG
MKR&[%\-RO'M^#..VG8SOF9 X^9LLFL^GRB-8SG?'C:%[8@U=/?[T.> F/(L:
M^P@6\S?,.M8PTX]_)O=S1AO.>/=U]K';]V#XV;.+]*?*3P+5SS(L:3ZQJ_7<
M5878/I('C!B<]NPBC5A"(B()G=VHFSTG.K5Z+,N4]H$L<V$HVK-_=,]!=T50
ML[1LAUH_#,[OIM/ZPVM5!/NH5KDQ=.W9)-IQ,Q1B"?S;&9?$L9YTB:><=\>V
M3:7+%/A,C4N_<?8LY\KD M.&WY@>"&$?Y4H[!K ]VTDCB)8ZQ2"<C(FL]Z.3
M<IU]*/<]&'[V[!R-.=:_:!RMTPFK/5_:$=E';L> P6;/9I#I>I>K:([I#)I\
M8UJNM0]BN0_#\G_8^GGO[[652O:+_AWLYHS^IW_5J8[\ U!+ 0(4 Q0    (
M /.#EE7IHKH2<"   'WE   .              "  0    !D-#(X-S,T9#AK
M+FAT;5!+ 0(4 Q0    ( /.#EE4I&:GO!F<  /O^ 0 1              "
M 9P@  !D-#(X-S,T9&5X,3 Q+FAT;5!+ 0(4 Q0    ( /.#EE5[T6G';@X
M /,J   1              "  =&'  !D-#(X-S,T9&5X.3DQ+FAT;5!+ 0(4
M Q0    ( /.#EE4[OB]8(@0  ',2   0              "  6Z6  !J;FHM
M,C R,C$R,C(N>'-D4$L! A0#%     @ \X.65=NW<1KX!0  !#@  !0
M         ( !OIH  &IN:BTR,#(R,3(R,E]D968N>&UL4$L! A0#%     @
M\X.658>KU_XU"   1EX  !0              ( !Z*   &IN:BTR,#(R,3(R
M,E]L86(N>&UL4$L! A0#%     @ \X.6510NAJ*U!0  3SP  !0
M     ( !3ZD  &IN:BTR,#(R,3(R,E]P<F4N>&UL4$L%!@     '  < O@$
' #:O      $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
